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Mycoplasma mycoides subsp. mycoides small colony type {MmmSC) is the
causative agent of contagious bovine pleuropneumonia (CBPP), a major disease of
cattle in Africa for which current vaccines exhibit a poor efficacy. MmmSC possesses
a capsular polysaccharide (CPS) believed to be an important virulence factor.
Antibodies directed against CPS are bactericidal in an in vitro growth inhibition test
(GIT). Therefore, CPS is a good vaccine candidate.
The aim of this thesis was to investigate the vaccine potential of MmmSC
CPS.
Before using CPS as a vaccine, the immunogenic structure of CPS needed to
be studied. MmmSC strains were tested with rabbit antisera (raised against different
MmmSC strains) in a GIT. The results showed that CPS was conserved between the
strains. Purified CPS from different MmmSC strains were then investigated with
monoclonal antibodies (mAbs) in an enzyme linked immunosorbent assay (ELISA).
It appeared that CPS from all the strains were recognised by the mAbs, except the
strain PG1 that had a low signal with two of the mAbs. GIT was used with mAbs that
recognised MmmSC CPS to test their growth inhibiting (GI) activity; all of the mAbs
used in the GIT were bactericidal.
The specificity of these mAbs was then investigated, using an ELISA, against
other mycoplasmas, Mycoplasma mycoides subsp. mycoides large colony and
Mycoplasma mycoides subsp. capri. The results obtained suggested that the mAbs
recognised at least three different epitopes on CPS.
A competitive ELISA was performed to clarify the number of epitopes that
these mAbs recognised. No conclusion could be drawn from this experiment since
the results were unclear.
Since antibodies to CPS are bactericidal in vitro, this suggested they were
protective against MmmSC. Passive immunisation of mice with a bactericidal mAb
directed against CPS was used to investigate the protective efficacy of anti-CPS
antibodies in vivo. After injection with the antibody, mice were challenged with an
MmmSC strain. The incidence and the duration of mycoplasmaemia were used to
assess the protection given by this antibody. No significant difference could be seen
between mice passively immunised with anti-CPS antibody and the control group,
suggesting that a bactericidal antibody was not protective in vivo in mice against
challenge withMmmSC.
The type of immune response to CPS was examined in three groups of cattle:
M/nmSC-intubated animals, CBPP-vaccinated and unvaccinated animals in contact
with MwrzSC-intubated cattle. The results showed that only a quarter of CBPP-
vaccinated cattle had an immune response against CPS. The immune response
against CPS in the three different groups was of IgM type even after a second
exposure to the pathogen where it could have been expected an IgG type immune
response.
The lack of immune response to CPS in cattle might be due to cross-reactions
with bovine lung. Cross-reactions between bovine lung and MmmSC CPS were
confirmed by western-blot with anti-MwwSC or anti-CPS sera from rabbits, mice
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and mAbs. It was not possible to know whether antibodies recognising both CPS and
bovine lung were present in anti-AfrwwSC cow sera because of a background signal
due to the secondary antibody specific for cow immunoglobulins.
To minimise the cost of CPS vaccine production, polysaccharides from other
sources could be used as a vaccine. A western-blot was then performed to examine
the cross-reactions between MmmSC CPS and carbohydrates from cereals with
A/mmSC-infected cow sera, MmmSC-immunised rabbit sera and mAbs. The results
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1. Introduction.
1.1. Contagious bovine pleuropneumonia (CBPP).
1.1.1. History.
In the 18th century, contagious bovine pleuropneumonia (CBPP), confined to
the alpine region ofEurope, disseminated with export of animals and was present in
many countries in the world. A policy of cattle movement restriction and slaughter of
diseased and suspect animals with compensation has allowed it to be eradicated from
the United States and many European countries, although outbreaks were reported in
France in 1980, in Spain in 1989, in Italy in 1990 and reappeared in Portugal in 1983.
In Australia, cattle movement restriction and slaughter have been associated with
vaccination. [i-4]. No outbreaks were reported in Europe in 1999. Despite mass
vaccination campaigns, CBPP has spread alarmingly in Africa. In 1999, the disease
was present in at least 27 countries in equatorial, central and southern Africa and it is
now considered as the most important threat to the cattle industry in Africa [5]. The
disease causes important economic losses due to mortality, loss of weight, reduced
work ability, reduced fertility and growth rate, cattle trade restriction, quarantine and
vaccination costs [4,6,7],
1.1.2. Clinical picture.
CBPP is an infectious disease caused by Mycoplasma mycoides subspecies
mycoides small colony (MmmSC) [8], This disease only affects cattle (species Bos)
and related animals such as buffalo, yak, bison and reindeer [2,4,9], although MmmSC
has been isolated from sheep's milk and from goats suffering from pneumonia [io]
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and from a goat reportedly suffering from contagious caprine pleuropneumonia [ii]
suggesting a possibility of transmission from sheep and goats to cattle. CBPP is
characterised by a severe exudative pleuropneumonia with secondary lymphatic and
vascular involvement leading to the typical lung lesions due to necrosis,
sequestration and encapsulation [4,7,9,12-14]. In adult cattle, the symptoms are
essentially restricted to the respiratory system [i5j. Young calves are rarely affected
and the disease is less severe, with infections generally causing arthritis, with lesions
in joints and synoviae instead of the lungs [15-17]. The incubation period is between 5
and 207 days [4]. Different forms of CBPP exist: in a herd nearly half of the animals
will develop the subacute/chronic form, 30 to 40% of animals will be affected by
either the acute form or the hyperacute form, the rest of the animals of the herd will
be resistant to the disease. Only the acute and hyperacute forms of the disease permit
a clinical diagnosis [9,13], In the chronic form, a cough may be the only symptom but
the post-mortem examination reveals necrotic lungs, walled off by fibrous tissue and
encapsulated to form sequestra containing viable MmmSC organisms [2,18-20]. In the
first stage of the acute form, the animal shows anorexia, irregular rumination, fall in
milk production with a moderate fever and persistent coughing. Excess ofmucus in
the nose and the mouth can be seen. In the next stage, there is no rumination and total
anorexia, the animal is in distress with painful respiration, is reluctant to move and
the animal dies soon after. At necropsy, a large excess of pleural fluid is found in the
thoracic cavity along with lung lesions [9,15,18-21]. The hyperacute form exhibits the
same clinical symptoms as the acute form, but is much accelerated and the animal
dies within a week. In adult cattle, the clinical signs are due to lesions developing in
the lungs.
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A large number of the cases are subclinical and cannot be detected except at
slaughter. The subacute form is the most dangerous form in the sense that it
maintains infection in a herd or an area undetected for months before lesions are seen
in abattoirs [13,15,22,23].
Lesions are usually unilateral, localised in the diaphragmatic lobe and present
a characteristic marbling appearance [2,17,211. They are thought to be caused by
autoimmune and hypersensitivity reactions [7,9],
Infected animals may recover from CBPP. These animals often present
sequestra of various sizes in one or both lungs. In some cases, lesions may resolve
leaving scarring on the lungs [2,6,17,24]. Recovered animals appear to be resistant to
reinfection with CBPP [6,20]. One experiment looked at the resistance of recovered
animals to CBPP reinfection by challenging cattle intravenously and by
endobronchial intubation (4 cattle for the intravenous route and 4 others for the
endobronchial route) with 50 ml of Gladysdale culture containing
1010 mycoplasmas/ml. The recovered animals challenged both by the intravenous and
the endobronchial route exhibited a secondary immune response as measured by the
complement-fixation test (the titres were lower for the cattle challenged
intrabronchially) but no mycoplasma could be found in the blood and tissues of any
of the animals [25]. However, the significance of these results may be questioned due
to the small size of the animal sample.
Since the sequestra contain viable mycoplasmas, recovered animals (with old
lesions) were thought to be a potential risk for healthy animals, as it has been
suggested that these lesions could break down under stress and transmit the
disease [26], However, when animals where submitted to different conditions of stress
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that can be encountered in Africa (exercise, starvation, water deprivation) it was
shown that it was difficult to break down these lesions. When stressed cattle with old
sequestra were put into contact with normal cattle, none of the latter was infected [24].
The main routes of transmission are by direct close contact between animals
excreting Flugge-type droplets by coughing and inhalation of bronchial
secretions [1,7,9,27,28]. Transplacental transmission has also been suggested as MmmSC
can cross the placental barrier [29], Experiments have shown the presence ofMmmSC
in calves born to cows with extensive lung lesions. The presence ofMmmSC could
not be due either to parturition or to suckling asMmmSC was isolated from various
tissues (lungs, kidney, spleen, lymph nodes, joints, blood) from a calf removed from
a cow at necropsy immediately after cow slaughter and from calves that did not suck
colostrum before being killed within 6 hours after birth. No CBPP lesions were
found in the calves but signs of arthritis were observed in the stifle joints. However,
it is not known whether these calves would develop CBPP and transmit the
disease [3oj. Other sources of contagion exist. ViableMmmSC has been isolated from
urine of cattle infected with CBPP. The small droplets coming from the splashing of
urine during micturition may be inhaled in the same way as droplets of bronchial
secretions pi]. The excretion ofMmmSC in a viable form was confirmed in another
experiment, where the titres ofMmmSC in urine ranged from 101 to 103 organisms
per ml. MmmSC was detected in urine from cattle with acute cases of CBPP [32].
Viable MmmSC has also been demonstrated in the nasal discharge of sick
animals [2,7] and in semen and preputial washings of bulls [33], Infection of cattle
through fomites and contaminated fodder has also been observed under experimental
conditions [34], It has also been reported that MmmSC can be isolated from ticks
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collected from CBPP-infected cattle, but so far the attempts to infect cattle with
MwmSC-infected ticks have been unsuccessful [35],
Differences in susceptibility to MmmSC infection have been noted.
Contradictory reports have been made concerning age susceptibility. It was
suggested that calves and old cattle were more often affected by CBPP, but with a
difference in the symptoms, calves showing signs of arthritis and old cattle
developing pleuropneumonia [6,15,20,22]. In other studies however, animals under the
age of 3 were highly susceptible to CBPP when compared to those over 3 years of
age since the mortality due to CBPP was higher and the lung lesions more severe in
the first group [36,37]. Differences have also been reported between beef steers and
dairy cows (the latter appearing to be more susceptible to infection), and between
breeds [15,20]. Cattle from breed Bos indicus (zebu) succumbed more severely to
CBPP than cattle from breed Bos taurns (European-type cattle), under the same
conditions, when the results were based on the death alone, but when the results were
based on the infection rate, no statistical difference could be seen between the 2 types
of cattle [38],
Few treatments are available to cure CBPP. Some antibiotics such as
Tilmicosin and Enrofloxacin have been shown to be mycoplasmacidal against
MmmSC [39]. In another study, Tilmicosin and Danofloxacin have been shown to
have both inhibitory and mycoplasmacidal activity in vitro on MmmSC strains [40].
However, the use of these substances is discouraged because, although they may
reduce the severity of the disease and improve the conditions of the infected animals,
they do not eliminate the mycoplasmas and can mask symptoms, leading to chronic
carriers that would be sources of infection [4,5,41].
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The disease seems to be less severe in Europe than in Africa, as seen with the
lack ofmortality and obvious morbidity in European outbreaks, although at necropsy
the infected animals present identical pathological lesions both in Africa and
Europe [5,27], The subacute and chronic forms of the disease are the most common in
Europe, the typical acute form is rare compared with Africa. This difference could be
due to the administration of antibiotics, good livestock management and the
immediate slaughtering of the animals. It was also suggested that it could be due to
the lower virulence of the European strains in comparison with African strain [27],
1.2. Causal agent of CBPP.
1.2.1. Mycoplasmas in general.
Mycoplasmas are the smallest self-replicating organisms. They are
extracellular parasites, widespread in humans, animals, plants and insects [42-44], The
majority of human and animal mycoplasmas colonise mucosal surfaces and generally
cause diseases involving the respiratory and the urogenital tracts, the mammary
glands, joints and eyes [42,45-47]. Some mycoplasmas have invasive properties and can
disseminate and affect serosal surfaces of the thoracic, abdominal and articular
cavities causing severe clinical cases [46], Mycoplasma infections seem to be host
specific but some of them can be pathogenic in one host species and colonise other
hosts without any pathogenicity [46,48], However, cases of pleuritis and diseases of the
lower respiratory tract in horses caused by Mycoplasma felis have been
reported [49,50].
In addition to their small size, mycoplasmas do not possess a cell wall and
consequently lack cell-wall associated proteins. They have a small genome with a
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low guanine plus cytosine content. In mycoplasmas, the UGA codon codes for
tryptophan (unlike other prokaryotes in which it is a stop codon) [5,46],
In order to colonise the host, some mycoplasmas need to adhere to the host
cells and the loss of adhesion means a loss of infectivity. In an experiment with
Mycoplasma pneumoniae, hamsters were intranasally inoculated with the wild type
strain B25C and its mutants which showed a significantly reduced attachment to
hamster tracheal rings. Hamsters inoculated with the wild type strain developed
pneumonia while hamsters infected with the mutants did not fsij. In vivo,
mycoplasmas adhere via their membrane surface to a wide range of substrates such
as mucous membranes, host-cell appendages and projections, and the host-cell
surface itself [44,48,52,53].
Mycoplasmas are able to evade the host immune response and to elicit
chronic inflammation by various mechanisms such as molecular mimicry,
immunosuppression, release of soluble antigens, formation of immune complexes
(that attract inflammatory cellular infiltrates to the area of infection by fixing
complement), antiphagocytic properties (due in a part to the presence of a capsule),
induction of autoantibodies (by behaving as potent mitogens for lymphocytes),
defective mycoplasmacidal antibodies (antibodies that have mycoplasmacidal
properties on resting mycoplasmas but not on multiplying mycoplasmas), altered
lymphocyte responsiveness and antigenic variation [43,52,54,55]. The lesions observed in
mycoplasmal disease are largely due to the host immunological reactivity rather than
the microorganisms themselves [42].
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1.2.2. Mycoplasma mycoides subspecies mycoides small
colony (MmmSC).
Mycoplasma mycoides subspecies mycoides small colony (MmmSC), the
causal agent of CBPP, was isolated in 1898 by Nocard and his collaborators [47,56],
This mycoplasma shares many immunological, biochemical and genetic properties
with Mycoplasma mycoides subspecies mycoides large colony (MmmLC),
Mycoplasma mycoides subspecies capri, Mycoplasma capricolum subspecies
capricohim, Mycoplasma capricolum subspecies capripneamoniae and Mycoplasma
species "bovine group 7" (Mbg7). These are all pathogens of cattle, sheep and goats
and comprise the "Mycoides cluster" [23,57]. Mycoplasmaputrefaciens was later added
to the "Mycoides cluster" when the clustering was based only on the 16S rRNA
Sequences [cited in 58],
MmmSC are invasive mycoplasmas causing systemic disease, they have been
found in the lungs, pleural fluid and thoracic lymph glands, in liver, spleen, kidney
and circulating blood [59],
As with all mycoplasmas, MmmSC does not possess a cell wall. MmmSC
grows readily in cell-free systems in serum-enriched medium, where the culture may
grow as visible threads. Virulent and moderately virulent MmmSC strains have been
shown to produce threads, unlike avirulent strains, however, the experiment was
performed with 4 strains only and this might not be true for all MmmSC strains [60],
MmmSC also grows readily on agar plates, where the colonies formed have a typical
"egg-fried" appearance [15,20,21]. The addition of glucose to the liquid culture medium
allows the formation of thicker threads indicating that the threads may be formed by
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products of glucose metabolism [6i], MmmSC is surrounded by a polysaccharide
capsule [2],
Some of the biochemical properties of MmmSC include resistance to
penicillin, the fermentation of glucose, the oxidation of maltose, trehalose and (at
low concentrations) mannose and glucosamine, and the reduction of tetrazolium.
MmmSC is unable to hydrolyse arginine [5,15,20,21].
The major precipitating antigen has been identified as a polysaccharide [62].
Other antigens have been identified after the study of the protein patterns of
13 MmmSC strains obtained by SDS-PAGE. Protein profiles demonstrated a high
similarity among the strains, with 49 to 59 distinct polypeptides ranging from 14 to
150 kDa. The major components had apparent molecular weights of 109, 95, 74, 67,
62, 60 and 48 kDa, the immunodominant proteins by western-blot had molecular
weights of 109, 95, 62 and 48 kDa [63,64],
Although closely related to the other mycoplasmas from the "Mycoides
cluster" and antigenically similar, MmmSC strains can be differentiated on the basis
of the insertion sequence analysis of their DNA. Insertion sequences are transposable
genetic elements of about 800 to 2,500 bp often present in multiple copies in
bacterial genomes. Three insertion sequences have been identified in MmmSC:
IS1296, IS1634 and ISMmyl [57,65,66]. The analysis of the IS1296 banding pattern of
64 MmmSC strains from various countries and continents showed that these strains
could be classified into two main clusters. One cluster is composed of the European
strains that form a single homogeneous group. The other cluster contains the African
and Australian strains with a more heterogeneous grouping; the type strain PG1, of
unknown origin, belongs to the cluster of strains from Africa and Australia [57], It was
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later discovered that the difference in the IS1296 profile between European and
African/Australian strains was due to a lack of an 8.84 kb genetic segment in the
DNA of the European isolates [67]. Unlike IS1296 that was found in a low copy
number in few strains ofMmmLC and Mbg7, IS1634 is highly specific for MmmSC.
No copies were found in any of the other members of the "Mycoides cluster", or in
other closely related mycoplasma species of ruminants [65], ISMmyl was found in
15 MmmSC strains; they showed the same banding pattern except for the type strain
PG1, the vaccine strain TiSR and the strain Afade. This insertion sequence is not
specific iorMmmSC since copies were also found in a,Mycoplasma bovis strain [66],
Differences in virulence among MmmSC strains have been observed. The
European strains are thought to be less virulent than their African counterparts
because the disease seems less severe in Europe. One experiment looked at the
immunological reactions in cattle infected either with the African strain Afade or the
European strain L2. Cattle were infected intrabronchially with 109 colony-forming
units (cfu) of strains Afade (one animal) and L2 (two animals), and two cattle were
put in contact with the infected cattle in each group. It was observed that Afade
induced stronger and earlier immune reactions than L2. Although only one strain
from Africa and from Europe were compared and a small number of animals was
used for each strain, the authors concluded that European strains were generally less
virulent than strains from Africa [68], However, the strong immune response to Afade
might clear the mycoplasma faster leaving less time to multiply in the host, and the
poorer immune response to L2 might be a consequence of immunosuppressive
properties of this strain, in that case, L2 could be considered as more virulent than
Afade.
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In addition, it was found that European strains were unable to oxidise
glycerol, unlike the African isolates. It was suggested that this inability could be a
factor in the reduced morbidity and mortality of CBPP in Europe since the oxidation
of glycerol by MmmSC strains produces hydrogen peroxide, which may be a
significant factor in the pathogenicity of CBPP, and consequently may contribute to
virulence [69], However, it should be noted that MmmSC strain KH3J, known for its
avirulence in cattle, was able to oxidise glycerol with a high rate of oxygen uptake
[J.B. March, personal communication], and consequently should be considered as a virulent strain
according to the authors' conclusions.
1.3. Immunity to CBPP.
Humoral and cell-mediated immunity seem to play an important part in the
recovery from and the protection against CBPP.
1.3.1. Humoral immunity.
Cattle recovered from CBPP are known to be resistant to subsequent
infections with MmmSC [6,20]. For this reason, it was thought that immunity might be
conferred by inoculating healthy animals with sera from these cattle. An experiment
has been carried out with 10 cows, 5 inoculated twice with 1 litre each of serum from
susceptible cattle and 5 inoculated twice with 1 litre each of serum from CBPP-
recovered animals. These animals were then put in contact with cattle infected with
MmmSC strain Gladysdale. The results showed that only one out of the five animals
given serum from CBPP-recovered cattle became infected. The four others had no
lesions due to CBPP, though MmmSC was found in two of them. All the cattle in the
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control group died from CBPP. These experiments suggested that cattle inoculated
with serum from recovered animals were protected against a challenge with
MmmSC [70] although the significance of the results was diminished due to the small
sample size of the animals.
This passive transfer of immunity has also been demonstrated in mice. Mice
inoculated subcutaneously with sera from mice immunised with a significant dose of
viable MmmSC and then challenged intraperitoneally with live microorganisms did
not develop bacteraemia [7ij. This test was also used to show that serum from cattle
inoculated intravenously with MmmSC produced "mouse-protective" antibody
(i.e. mice inoculated with MmmSC immune serum from cattle did not exhibit
mycoplasmaemia after challenge with MmmSC) [72], Therefore, antibodies seem
important in the immunity toMmmSC.
However, when the antibody titre was measured by complement-fixation test
(CF test), it did not seem to have correlation between the antibody titre and
protection against CBPP. In 30 cattle vaccinated with freeze-dried mycoplasmas,
only 13 exhibited CF antibodies after vaccination. When these animals were
challenged by in-contact method, 29 out of 30 animals had CF antibodies following
challenge, and 24 out of 30 were resistant to CBPP. In the 15 unvaccinated control
animals, all of them showed CF antibodies following in-contact challenge and all of
them except one animal were susceptible to CBPP [73], This demonstrated that
vaccination is not good at inducing CF antibodies, unlike infection.
These results do not necessarily mean that humoral immune response is not
important in protection against the disease. They rather suggest that other
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mechanisms, along with humoral immune response, might be involved in protection
against MmmSC like cell-mediated immunity.
1.3.2. Cell-mediated immunity.
Cell-mediated immunity against CBPP was measured by three different
methods: transformation of lymphocytes sensitised by a specific antigen, inhibition
of leukocyte migration by a specific antigen and an intradermal allergic reaction. A
study looking for these three effects has been performed with MmmSC in (i)
susceptible control cattle, (ii) cattle vaccinated with Tj broth culture and (iii) cattle
infected endobronchially with MmmSC [74], The intradermal allergic test consisted of
the injection of membrane antigens or polysaccharide ofMmmSC in the neck and the
measurement of any increase of skin thickness. A positive reaction was observed in
all infected cattle, but not in control and vaccinated animals. Lymphocyte
transformation was measured by labelling DNA with tritiated thymidine and
quantifying its uptake. The results were expressed using a lymphocyte transformation
index with the ratio ofmean counts per minute per culture in the presence of antigen
being compared to the mean counts per minute per culture in the absence of antigen.
Lymphocyte proliferation was observed in five out of six infected animals and two
out of six vaccinated cattle. Only a slight difference was seen in control animals [74].
Inhibition of leukocyte migration was studied using polystyrene leukocyte
migration plates with the results given using a leukocyte migration index that was the
mean of migration area in the presence of antigen divided by the mean of migration
area in the absence of antigen. In infected animals, inhibition of the migration was
observed after 30 days following infection. Vaccinated animals and control cattle did
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not show any inhibition of migration. The previous results indicate that cell-mediated
immunity is involved in infection with MmmSC but not in vaccinated animals since
the results of this group of animals is similar to those of the control cattle [74],
The cell-mediated immunity was explored in endobronchially infected
animals and TiSR/Ti44-vaccinated cattle challenged by contact with the infected
animals. In the group of vaccinated cattle, animals resistant to CBPP exhibited an
increase of the CD4 T-cell population after challenge, with a significant release of
interferon y in vitro whereas vaccinated animals that died of CBPP did not. In
infected cattle, animals that died of acute CBPP did not show an increase in the CD4
T-cell population and no production of interferon y could be detected in vitro, while
animals with inapparent disease demonstrated an increase in the CD4 T-cell
population with release of interferon y in vitro. Animals with subclinical CBPP
showed intermediaiy results [75]. These results suggested the involvement of cell-
mediated immunity with CD4 T cells in protection of cattle against CBPP.
1.4. Vaccines against CBPP.
The first vaccines used consisted of a subcutaneous inoculation ofMmmSC-
infected pleural fluid. In the early 1900s, these vaccines were replaced by the
subcutaneous injection of field broth cultures ofMmmSC but these vaccines were not
reliable since batch to batch variation in the number of live organisms in the
inoculated dose occurred, often resulting in post-vaccinal reactions or poor
efficacy [is,76], Egg-based vaccines were used in Africa in the 1950s and early 1960s,
made by growing MmmSC in embryonated eggs [77], They were subsequently
abandoned because of the severe post-vaccinal reactions at the site of injection and in
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the lungs [78,79], Inactivated vaccines have also been tested but have not progressed
beyond the experimental stages as they did not induce good protection p,7i]. It has
been reported that subcutaneous vaccination of cattle with killed MmmSC
Gladysdale strain provided a complete protection to CBPP when cattle were
challenged by direct contact with CBPP-infected animals. But it should be noted that
this was obtained by using a very large dose (20 ml) of killed mycoplasmas
inoculated with complete Freund's adjuvant [so].
The current vaccines used in Africa are attenuated freeze-dried broth culture
vaccines containing viable microorganisms from strains Ti44 (has still some residual
virulence in some breeds), TiSR (streptomycin resistant, causes less severe post¬
vaccinal reactions than Ti44 while maintaining the same level of immunogenicity),
KH3J and KH3JSR (do not cause any reactions in cattle but confer a poor immunity,
the latter is streptomycin resistant). Ti44 and TjSR are the most commonly used [3,7i],
The minimum dose of vaccine recommended by the Office International des
Epizooties is 107 mycoplasmas per animal. This dose has been shown to be sufficient
to produce immunity in cattle in an experiment withMmmSC vaccine strain Ti [si], A
study examining the storage of freeze-dried Ti vaccine has shown that the vaccine
was still potent at 4°C, 23 °C and 42°C after 14 months, 4 months and 3 weeks
respectively [82],
As these vaccines contain live organisms attenuated by serial passages, one
concern was the risk of reversion to full virulence when they are used, but no
increase in virulence of the Ti and KH3J strains has been shown after inoculation [83].
However, with Ti44 vaccine, it has recently been reported that cattle in CBPP-free
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areas, vaccinated with Ti44, with no contact with other herds, developed CBPP. It
was suspected that these outbreaks might be due to the vaccination [84],
Different routes are used to administer the vaccines. In English-speaking
countries, the vaccine is injected into the tail tip, while in French-speaking countries,
a subcutaneous inoculation into the chest wall or the shoulder is preferred [2]. These
two routes of inoculation have been shown to give a solid immunity to cattle
immunised with MmmSC Ti strain, unlike the intradermal route where a quarter of
inoculated cattle developed typical lung lesions after exposure to CBPP by contact
with Mm/nSC-infected animals [85], As the subcutaneous route was as effective as the
tail-tip route in vaccination against CBPP, it was suggested that the former should be
preferred in vaccination programmes as it is faster, more convenient and cleaner [85]
and because the inoculation into the tail tip is difficult due to the high pressures
required [2],
The length of the immunity induced after vaccination with Ti broth vaccine
has been investigated in different studies. One experiment compared the protection
against CBPP in cattle vaccinated with 0.5 ml of Ti broth vaccine into the tail tip
then challenged 6 months and one year after vaccination by contact with
endobronchially-infected animals. The results showed that cattle challenged
6 months after vaccination did not show MmmSC in their respiratory system, while
mycoplasmas were found in cattle challenged one year after vaccination [86],
suggesting the immunity conferred by the vaccination lasted less than a year.
However, in other studies, antibodies were demonstrated in cattle 23 months after
vaccination (even though it does not mean cattle are protected against CBPP) [87].
Cattle challenged by contact with MwnSC-infected animals for 9.5 months, two
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years after being vaccinated with Tj broth culture (0.5 ml dose containing 3xl010
organisms/ml), did not show serological responses to MmmSC, did not present any
lesions of CBPP and no MmmSC were found after challenge [88], These results
suggested that vaccination with Ti broth culture protected cattle against CBPP for at
least two years. The effect of a booster dose on the immunity of cattle to CBPP
vaccines was also investigated [89], For this experiment, cattle were vaccinated with
either one ml of a Formalin-inactivated oil-adjuvanted Gladysdale vaccine or with
0.5 ml of live Ti vaccine strain. Each group contained 10 animals. Half the cattle
from each vaccinated group received a booster dose of the appropriate vaccine three
weeks after the primary vaccination. Three months after vaccination, vaccinated
cattle were then challenged by contact with animals intubated with MmmSC strain
Gladysdale. All vaccinated cattle survived the challenge while the control and the
intubated animals died of CBPP. One animal vaccinated with the inactivated
adjuvanted vaccine that had received a booster dose showed congested lungs at
necropsy and MmmSC were isolated from this animal. From this study, it was
concluded that a booster dose was not necessary when animals have a strong
immunity after vaccination [89].
Freeze-dried vaccines are now used. They might give different protection
compared to broth culture vaccines. It is commonly accepted that Ti44 and TiSR
vaccines induce only a short lasting immunity (less than a year) and regular
vaccinations are needed [70,90,91]. Recent field trials have shown that the protection
induced was not satisfactory. In the first trial, the protection rate for both freeze-dried
Ti44 and TiSR vaccines three months after vaccination was 37% after challenge by
contact with intubated animals [92], In the second trial, the protection rate was 59%
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(for T]44 vaccine) and 68.2% (for TjSR vaccine) when the vaccinated animals were
challenged three months after vaccination. When the vaccinated cattle were
challenged 15 months after vaccination, the protection rate was 28% for TjSR
vaccine while the protection rate was 78.2% for Ti44 vaccine. A second vaccination
one year after the primary vaccination gave a better protection against CBPP as seen
with the protection rate of 80.4% (for TiSR vaccine) and 95% (for Ti44 vaccine) in
the animals challenged three months following the second vaccination [93],
Studies have also shown that the efficiency ofTi broth culture vaccines could
be affected by the use of antibiotics or by infection of the vaccinated animals by
other diseases. A comparison of vaccinated cattle, treated or not treated with the
antibiotic Tylosin (10 mg/kg) one week or four weeks after vaccination (with 0.5 ml
ofTi broth culture vaccine at 3.3xl09 organisms/ml) showed that in the group treated
with Tylosin four weeks after vaccination, animals presented lesions typical of CBPP
after challenge by the in-contact method with animals intubated with MmmSC strain
Gladysdale. The untreated vaccinated animals had no lesions. In the group treated
with Tylosin one week after vaccination, some cattle had lesions that were not
related to CBPP [94], Since Tylosin might kill the mycoplasmas, this suggests that live
mycoplasmas are important in inducing protection against CBPP.
Intercurrent diseases can also affect the efficacy of vaccines. A study has
shown that half the cattle infected with trypanosomes prior to vaccination against
MmmSC (minimum dose of 108 cfu of Ti broth culture vaccine) contracted CBPP
after challenge by contact with CBPP-infected animals [95], suggesting trypanosome
infections depress the protective immune response engendered by CBPP vaccination
(Trypanosoma congolense and Trypanosoma vivax are two trypanosomes largely
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spread in Nigeria where CBPP is also present). It has also been demonstrated that
animals tail-tip vaccinated with Ti broth vaccine that were already severely infected
with Dermatophilus congolensis (causing dermatophilosis, a disease prevalent in
Africa) had an immune response (measured by haemagglutination test) to CBPP
vaccine markedly lower than animals mildly infected and control cattle [96], although
immune response does not necessarily mean protection.
1.5. Capsular polysaccharide (CPS).
MmmSC possesses a capsule made of polysaccharide [4], This antigen, known
to play a part in the virulence of strains ofMmmSC, is found in broth culture and in
tissues from infected animals (heart, lungs, pleural fluid, and urine) [23],
1.5.1. Structure of CPS.
The capsular polysaccharide (CPS) of MmmSC forms a slime layer and
comprises about 10% of the dry weight of cells in young culture [6ij. This
polysaccharide has an apparent high molecular weight (several hundred
thousand kDa) [97], An early study of the structure was performed using hydrolysis
and has allowed the main sugar component to be identified as galactose [98], Further
experiments have extracted this polysaccharide using warm aqueous phenol before
digestion by partial acid hydrolysis. These digests produced a galactobiose due to the
degradation of a disaccharide with the structure 6-0-P-D-galactofuranosyl-D-
galactose [99], Additionally, electron impact mass spectrometry has indicated the
presence of fucose, mannose, galactose, glucose, A-acetylated galactosamine and N-
acetylated glucosamine in the proportions 1:2:4:1:4:8 [9T\. However, a more recent
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study showed that CPS was composed ofgalactose, mannose and glucose, but since a
carbohydrate component present in the culture medium contains mannose and
glucose, it was suggested the CPS was composed of galactose only, the other sugars
coming from the culture medium [ioo].
CPS is the main complement-fixing antigen. Experiments on the inhibition of
complement fixation in the presence of sugars or disaccharides have suggested that
this carbohydrate possessed terminal residues with the structure (3-glucopyranosyl-
galactofuranosyl, as the monosaccharide (3-glucopyranosyl and the disaccharide 1-6-
P-glucopyranosyl-galactose were the most efficient inhibitors [ioij.
Cross-reactions have been observed between CPS and barley and oat glucans
and polysaccharides from coccobacillus, agar, gum guar, from bovine, human and
rabbit lungs [4,23,102,103]. Agar consists of P-l-linked D-galactopyranose connected by
1-4 linkage to L-galactose. In gum guar, P-l-4-linked D-mannopyranose units are
linked with D-galactopyranose units by 1-6 linkages [102]. The polysaccharide
produced by bovine lung epithelial cells contains D-galactose [i04]. Its structure
consists of a main chain of D-galactopyranose units connected by P-l-6 linkages.
Every second unit of this backbone structure has one D-galactopyranose attached in
the P-l-3 position [105,106]. Bovine pneumogalactan may also contain a small
proportion of glucuronic acid [107]. The linkages in agar, gum guar and
pneumogalactan are 1-3 and 1-6 and the sugars of these polysaccharides are in
pyranose form. Since antibodies to CPS cross-react with these polysaccharides, CPS
may contain these linkages as well. CPS is composed mainly of sugars in the
furanose forms, but it may also contain some galactopyranose rings. It is possible
that both ring types are present in CPS [102].
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The antigenic relation between CPS and pneumogalactan might play a role in
the pathogenesis of CBPP. It was suggested this could lead to a partial immune
tolerance of the host to MmmSC, to autoimmune allergic type reaction if the immune
tolerance is overcome, and anti-galactan antibodies are produced [17,102],
1.5.2. Role of the CPS.
1.5.2.1. Effects on the host.
In infected animals, galactan can be found in various part of the body
(circulating blood, lung fluid, pleural fluid, pericardial fluid, urine) [2,20] in such
quantities that it saturates the antibodies creating the formation of circulating
immunocomplexes that damage pulmonary cells [2,108].
CPS has been shown to have toxic effects, as it can cause necrosis in cattle in
the absence of mycoplasmas [4,23]. Moreover, when injected intravenously, calves
suffered from transient apnoea, increased arterial and decreased systemic blood
pressure. Haemorrhages associated with alveolar ducts and vessel walls, areas of
pulmonary oedema and capillary thrombosis were observed at the necropsy [109J. In
another similar study, some of the animals died following the injection of CPS and
autopsies revealed a congestion of the trachea, bronchial tubes, lungs, jejunum, ileum
and small colon, along with haemorrhaging in the right ventricle [no]. In addition to
its inflammatory action, CPS may also stimulate the development of connective
tissue around the sequestra [2],
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1.5.2.2. Relation to virulence.
Differences in virulence have been observed between strains ofMmmSC. For
instance, comparison of two previously used vaccine strains, V5 and KH3J, showed
that V5 could induce local reactions at the tail tip (the site of injection), which in
some cases proved fatal. None of these effects have been noted with KH3J [cited in 111].
Inoculation intraperitoneal^ or intravenously with these two strains in mice resulted
in extended bacteraemia with the V5 strain [111,112]. These results suggest a greater
virulence for V5 than for KH3J.
Virulence ofMmmSC strains has been shown to be related to the amount of
CPS produced by these strains. A comparison of cattle which had received either an
injection of CPS at 0.66 mg/kg, or at 0.22 mg/kg, followed by a subcutaneous
injection of mycoplasmas (109 cfu/ml of V5 strain), showed that cattle inoculated
with the higher dose of CPS had a more pronounced mycoplasmaemia than the group
inoculated with the lower dose or than the control group (inoculated with
mycoplasmas only). In addition, two groups of cattle were injected with CPS: one
with CPS from Gladysdale (a virulent strain), the other one with CPS from KH3J (an
avirulent strain). The origin of the CPS was different but all the animals received the
same concentration (2 mg/kg). These animals then received an injection of
mycoplasmas of the V5 strain. Both groups showed similar proportions of samples
positive for the presence of mycoplasmas by blood culture [110]. The conclusion of
this study was that higher levels of CPS increased the virulence of a strain because
animals treated with the highest dose of CPS had a more marked bacteraemia. Also,
when CPS from a virulent strain and from an avirulent strain were injected at the
same concentration, they produced the same effects. This suggests that the virulent
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strains produce more CPS than their avirulent counterparts, rather than increased
virulence being due to differences between the CPS of Gladysdale and KH3J.
Moreover, cattle inoculated intravenously with CPS at the same time as cultures of
avirulent KH3J and of virulent V5 strains had an earlier and a prolonged
mycoplasmaemia when compared with cattle inoculated with the same strains but
without the addition of CPS [113].
In an experiment studying two colony types (smooth and rough), isolated in a
steer previously infected with Gladysdale, it appeared that the smooth colony type,
associated with a higher production of CPS than in the rough type, produced a
greater loss of weight of cattle than the rough type (cattle infected endobronchial^
with 50 ml of broth culture containing 109 cfu/ml for each colony type). Cattle
infected with the smooth type also developed arthritis and pleural serofibrinous
exudate [114].
Other studies have also shown that MmmSC mutant strains with reduced
capsular synthesis were phagocytosed more effectively by polymorphonuclear
lymphocytes in vitro [4],
Therefore, CPS is an important virulence factor since it is involved in the
spread of the mycoplasmas and in the pathogenesis ofCBPP.
1.5.3. Antibodies against CPS.
The growth inhibition test (GIT) consists of placing filter paper discs
impregnated with antiserum in contact with mycoplasmas cultured on agar plates.
Three days later the zone of inhibition between the disc and the mycoplasmas is
measured. Two experiments have shown that the antibodies responsible for the
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inhibition were directed against CPS. The first study [lis] used monoclonal antibodies
produced after immunisation with membrane fraction. Some of these antibodies were
shown to inhibit the growth of mycoplasmas. Subsequently, they were tested against
MmmSC antigens either treated or not treated with periodate. The results showed that
periodate treatment prevented the binding of antibodies, suggesting that the
recognised antigens were polysaccharides. The second study [H6j used rabbit antisera
obtained by immunisation with MmmSC. Sera that gave positive results in GIT were
used. When these antisera were pre-absorbed with purified CPS before use, the
inhibition activity disappeared, showing it was caused by anti-CPS antibodies.
Moreover, comparison between the sensitivity of a strain to growth-inhibiting
antisera and the CPS production by this same strain showed an inverse correlation,
i.e. the more CPS produced by a strain, the less it is inhibited by antisera. The
inhibiting antibodies are therefore those directed against CPS.
1.6. CPS in other microorganisms.
1.6.1. CPS and virulence.
Many microorganisms possess a capsule consisting of polysaccharides. This
CPS is often a virulence factor. In Erwinia stewarttii, the most virulent strains are
those that produce the most extracellular polysaccharides [ii7]. Similarly, in
Mycoplasma gallisepticum, those strains that presented a dense-staining capsule after
staining with ruthenium red were those that had a greater pathogenicity in
chickens [lis]. The presence or the amount of CPS produced has been reported to be
related to virulence in Klebsiella pneumoniae [ii9], Vibrio vulnificus [120,121],
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Cryptococcus neoformcms [122], Mycoplasma dispar [123], Bacteroides fragilis [124],
Streptococcus suis [125] and Rhodococcus equi [126].
The presence of CPS is associated with the dissemination of several bacteria
in the host. It has been shown with Actinobacillus pleuropneumonias that
encapsulated strains were able to produce bacteraemia in mice, unlike strains that did
not produce a capsule [127]. Another study, using mice challenged intraperitoneally
with a strain of Escherichia coli and a capsule-defective mutant of the same strain,
has shown that LD50 (the lethal dose able to kill half of the animals in a specific
group) was higher for the group infected with the mutant strain than for the group
inoculated with the capsulated isolate, supporting the important role of CPS in
pathogenesis [128].
The role of CPS in colonisation via adhesion is not well established. In mice
fed either with encapsulated or non-capsulated strains ofKlebsiella pneumoniae, the
encapsulated strain colonised the intestinal tract at a level of 108 cfu/g of faeces,
while the non-capsulated strain had a level of 104 cfu/g of faeces. When mice were
fed simultaneously with both the capsulated and non-capsulated strains, the acapsular
isolate was rapidly outcompeted by the capsular strain. This suggested that CPS has
an important role in the colonisation of the intestinal tract by Klebsiella
pneumoniae [129]. An adhesion experiment was also performed using a capsule-
defective mutant and an encapsulated wild-type strain of Klebsiella pneumonia. It
showed that the mutant adhered more efficiently to intestinal cell lines, laryngeal
cells and lung epithelial cells than the wild-type strain. However, when the
experiment was repeated with mucus-producing cells, the acapsular strain adhered
less efficiently to the cells than the encapsulated strains. This demonstrated that CPS
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of Klebsiella pneumoniae partially inhibits the adhesion of the bacteria to epithelial
cells unless they produce mucus [130]. Another adhesion experiment with capsulated
and non-capsulated strains of Pasteurella multocida has shown that the non¬
capsulated variant adhered in significantly higher numbers to respiratory tract cells.
Unlike Klebsiella pneumoniae, the acapsular isolate was shown to have a greater
affinity for the respiratory tract mucus [i3i].
However, it should be mentioned that this was observed with CPS from other
bacteria and there is no evidence that MmmSC CPS is involved in adhesion of these
mycoplasmas, nor is it clear the importance of adhesion inMmmSC pathogenicity.
CPS has been shown to protect bacteria from phagocytosis. Encapsulated
microorganisms are resistant to phagocytosis unless they are opsonised. In
Cryptococcus neoformans, the phagocytosis by alveolar macrophages was also
influenced by the size of the capsule present on different strains. Phagocytic cells
were less able to phagocytose strains with the CPS with the highest molecular
size [132], In addition to its antiphagocytic property, CPS is also able to influence the
host immune response by activation of phagocytic cells and complement components
of the alternative pathways to the induction of specific antibody, T-suppressor cells,
delayed type hypersensitivity response and cytokines [122]. The CPS ofMycoplasma
dispar, for example, has been shown to possess immunosuppressive properties since
it is able to suppress the production of tumour necrosis factor and interleukin 1 by
bovine alveolar macrophages [123].
Components of CPS may also "hide" the bacteria from the host immune
system, i.e. CPS would appear as a self-antigen to the host that therefore would not
elicit an immune response to CPS (capsules containing sialic acid for instance) [133].
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1.6.2. Antibodies against CPS and conjugate vaccines.
Capsular polysaccharides are important virulence factors that help
microorganisms invade by protecting the bacterium from the host defences, i.e. they
prevent phagocytosis in presence of complement alone [87] or in absence of specific
antibodies [125,134,135]. Antibodies against polysaccharides have been shown to be
protective against invasive diseases caused by encapsulated bacteria [i36j. In
Actinobacillus pleuropneumoniae, the main opsonic antibodies are directed against
CPS. Additionally, an antiserum pre-absorbed with purified CPS was still able to
opsonise the bacteria but phagocytosis was reduced [127].
Various studies have shown that antibodies directed against CPS from
different bacteria have a protective effect against disease. Subjects immunised with
Vi+ strains ofSalmonella typhi or with sera taken from subjects immunised with Vi+
strains were protected from infection, while those immunised with Vi- strains were
not [137], Only vaccines able to elicit the production of anti-CPS antibodies gave
efficient protection. Similarly, immunisation of rats with purified CPS from
Klebsiella pneumoniae protected them against lethal experimental pneumonia [138],
Rats that received an intravenous injection of monoclonal antibodies raised against
CPS (10 mg/kg), prior to an intrabronchial inoculation with a virulent strain of
Klebsiella pneumoniae, presented lung lesions and inflammation signs at a much
reduced rate compared to rats in a control group that presented a pneumonia
associated with haemorrhage and necrosis. Treatment with monoclonal antibodies
did not prevent the penetration of organisms in the interalveolar space and the first
inflammatory reactions were comparable between the treated group and the control
group. However, the administration of monoclonal antibodies increased the bacterial
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clearance in the spleen and the liver [ii9j. When hamsters were vaccinated
intramuscularly or intranasally with the polysaccharide purified from Mycoplasma
pneumoniae, then challenged intranasally with the microorganism, the number of
viable organisms in the lung was significantly reduced and the lung lesions were less
severe than in the unvaccinated group [139].
Vaccines consisting of purified CPS only are not feasible because, in most
cases, CPS is a poor immunogen and does not induce a cellular immunity. CPS is a
thymus-independent (TI) antigen [i40], TI antigens are divided in two groups: type 1
TI (Til) antigens and type 2 TI (TI2) antigens. Til antigens are bacterial products
that tend to have attached lipids and function by non-specific polyclonal activation of
most B cells. For example, bacterial lipopolysaccharides are Til antigens. They do
not induce immunological memory, isotype switching of antibodies and T-helper cell
involvement [i36,i4i], TI2 antigens are high molecular weight polymers with repeating
units, slowly metabolised in vivo, such as CPS. They may be tolerogenic in large
doses and generate few (if any) memory B cells [136,141,142]. Some TI2 antigens may
activate the alternative complement pathway [142]. Unlike Til antigens, they do not
act as B-cell mitogens and can only activate mature B cells by cross-linking surface
exposed immunoglobulins, leading to the production of antigen-specific
antibodies [Hi], These antibodies have a low affinity IgM and IgG isotypes [140,143].
The immune response to TI antigens is short-lived since T cells are not involved in
the development of the immune response [i4oj.
Thymus-dependent (TD) antigens are soluble proteins, whole cells, viruses
and parasites. The immune response to TD antigens (which require T-cell help to
elicit an immune response) is characterised by a long lasting immune response with
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the production of memory B and T cells. They produce high affinity antibodies of
multiple isotype. The memory B cells will allow a quicker response upon a
secondary exposure to the antigen [i36,i4i].
Antibodies to polysaccharides have been shown to protect against diseases,
which make them good candidates as vaccines. To be used as a vaccine, the strategy
is to convert TI antigens into TD antigens. This can be achieved by conjugating CPS
to immunogenic proteins. In Salmonella typhi, Vi antigen has been conjugated to
porins. Both porins and Vi antigen were isolated from the same microorganism. The
inoculation of this conjugate induced both systemic and mucosal immune responses.
The protection provided against Salmonella typhi was also better than the one
observed with Vi alone [144].
Such vaccines have already been successfully developed (pneumococcal [145]
and meningococcal vaccines [146]).
1.7. Aims.
CBPP, caused by MmmSC, is a disease of major importance in Africa. In
Europe and the USA, CBPP has been eradicated mainly by cattle movement
restriction and slaughter associated with compensation. These measures are hard to
apply in Africa because of the political, social and cultural situations in many
countries and of the cost involved. Therefore, the only realistic way to eradicate
CBPP in Africa at present is by vaccination. Vaccines against CBPP exist but they
are not efficient enough and produce a short lasting immunity. As a consequence a
better vaccine needs to be found.
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The most "protective" antigens against a pathogen are generally the toxic and
virulence factors of the pathogen [4ij. MmmSC possesses CPS that has been shown to
be toxic and to play an important part in the virulence ofMmmSC strains.
In other microorganisms, antibodies against CPS have been shown to be
protective against the disease. Since CPS are thymus-independent antigens, they
need to be conjugated to a protein to efficiently produce antibodies and elicit
immunological memory. This has led to the development of CPS-conjugate vaccines.
Another important consideration for CPS vaccines is the duration of the
immunity induced. Studies on the duration of the protection conferred by
polysaccharide vaccines, such as pneumococcal multivalent vaccine and Vi capsular
polysaccharide vaccine have suggested they were efficient for between 5 to
10 years [147],
For the reasons cited above, CPS ofMmmSC seems a good candidate vaccine
and merits further investigations.
The aim of my project was to investigate the vaccine potential ofMmmSC
CPS.
The immunogenic structure of CPS needed to be investigated. A vaccine
should be efficient against most, if not all, strains of MmmSC. Therefore, it was
necessary to know if CPS was conserved between MmmSC strains and if some
epitopes were present only in some of the strains. The bactericidal activity of anti-
CPS antibodies should also be examined since some epitopes may produce
antibodies with mycoplasmacidal activity and some others may not: the former
would then be more important in protection against CBPP, assuming the protection is
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conferred by anti-CPS antibodies. MmmSC CPS should also be compared with the
CPS from other mycoplasmas in the "Mycoides cluster".
The protective efficacy of CPS-specific antibodies should also be explored in
vivo. This cannot be done in the natural host ofMmmSC because of the large size of
the animals and the cost involved. Mice inoculated with MmmSC intraperitoneal^
have been shown to present bacteraemia without any signs of disease [m,i48]. The
protective efficacy of sera against MmmSC has already been tested in mice: mice
inoculated subcutaneously with immune mouse serum raised against MmmSC or
with serum from cattle inoculated intravenously with MmmSC did not develop
mycoplasmaemia after challenge with MmmSC [71,72,148]. Moreover, comparisons of
virulence between different MmmSC strains, based on the duration of
mycoplasmaemia in mice, showed a correlation between the virulence observed in
mice and that observed in cattle [111,148,149]. Consequently, although the mice are not a
perfect model for CBPP, passive immunisation of mice with anti-CPS bactericidal
antibody followed by challenge with live MmmSC could help us to evaluate the
efficacy of this antibody against mycoplasma infection.
Current vaccines lack efficacy in protecting cattle against CBPP. The study of
the immune response against CPS in vaccinated cattle could provide an answer. A
poor immune response to CPS might explain the results obtained with vaccination.
Therefore it was decided to examine the immune response to MmmSC CPS
following vaccination and natural infection.
A vaccine should be as safe as possible with minimal post-vaccinal reactions.
Serological similarities have been reported between CPS and bovine lung.
Antibodies recognising both CPS and lung tissue could lead to immunopathology in
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cattle. Thus, the presence of this kind of antibodies in naturally infected cattle will be
examined. The antigenic similarity between CPS and bovine lungs will also be
studied with monoclonal antibodies to try to identify epitopes present on CPS that
might not be found on bovine lungs.
CPS shares serological similarities with polysaccharides from various
sources. In order to reduce the cost of the production of a CPS vaccine (due to the
growth ofMmmSC in specific facilities and CPS purification), other polysaccharides,
such as polysaccharides from cereals, could be used instead of CPS. To explore this
issue, the antigenic similarities between CPS and carbohydrates from various cereals
will be investigated.
In some other microorganisms, CPS seems to play a part in the adhesion to
the host cell. Little is known about the adhesion ofMmmSC. MmmSC CPS is a
virulence factor and could be involved in adhesion, increasing the pathogenicity of
the strain. The role ofCPS in adhesion ofMmmSC will then be explored.
The results obtained will then be discussed.
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2. Materials and methods.
2.1. Mycoplasma strains and growth conditions.
Mycoplasma mycoides subspecies mycoides SC (MmmSC) strains used are
shown in Table 1. MmmSC strains were grown in Gourlay's broth (GB, see
Appendices), casein medium (CM, see Appendices) and on Gourlay's agar (GA, see
Appendices).
Table 1MmmSC strains used.
Strains Origin Isolation date Host/specimen type Source
PG1 type strain unknown 1931 cattle LNTV1
Gemu Goffa Ethiopia 1974 cattle LNIV1
Filfili Senegal pre-1988 cattle LNTV1
Ti44 Tanzania 1952 cattle/ vaccine strain BVI2
TiSR Tanzania 1952 cattle/ vaccine strain BVI2
kh3j Sudan 1940 cattle/ vaccine strain LNTV1
Tanl Tanzania 1996 cattle ADRI3
Tan8 Tanzania 1996 cattle/ pleural fluid ADRI3
N6 Botswana 1996 cattle/ lung NVL4
M375 Botswana 1995 cattle/ lung NVL4
Afade Chad 1968 cattle VLA5
Gladysdale Australia pre-1964 cattle VLA5
V5 Australia 1936 cattle/ vaccine strain VLA5
6479 Italy 1992 cattle/ lung LNTV1
0697 Spain 1989 cattle LNIV1
P02 France 1980 cattle/ lung LNIV1
B773 Portugal 1991 cattle/ semen LNIV1
425 Portugal 1993 goat/ lung LNIV1
b820/124 Portugal 1991 cattle/ preputial washing LNIV1
0512 Portugal 1993 sheep/ milk LNIV1
BF138 Italy 1992 buffalo LNIV1
B103 Portugal 1986 cattle/ lung LNIV1
2Botswana Vaccine Institute (BVI), Gaborone, Botswana - Benedict Lema, Animal Diseases Institute
(ADRI), Dar-Es-Salaam, Tanzania - "'Willie Amanlu, NVL, Gaborone, Botswana - 5Robin Nicholas,
Veterinary Laboratories Agency (VLA), Addlestone, United Kingdom.
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2.2. Antisera.
2.2.1. Anti-MmmSC rabbit polyclonal sera.
Rabbit hyperimmune sera used are shown in Table 2. Sera from Moredun
Research Institute (MRI) were produced according to the following protocol. The
aqueous solution was made with 625 pi ofwhole mycoplasmas (5-10 mg/ml) added
to the same volume of 0.02% glutaraldehyde solution (Sigma, G-6257) and mixed
for 30 min. A volume equal to 1.25 ml of 0.01 M glycine solution (Fisher scientific,
G/0800/60) was added to the mixture. Then the solution was mixed and left at room
temperature for 5 min. Fifty pi of 1% thimerosal solution (Sigma, T-5125) was
added. The aqueous solution was mixed with an equal volume of adjuvant Montanide
ISA 50 (Seppic). The rabbits were immunised twice subcutaneously with an interval
of II days. One month later, the rabbits received an intravenous injection of the
aqueous solution without adjuvant and they were bled approximately 5 days later.
Table 2. Anti-MmmSC rabbit polyclonal sera.
Strains Source Strains Source
PG1 LNIV1 V5 MRI2
Gemu Goffa LNIV1 6479 LNIV1
Filfili LNIV1 0697 LNIV1
Ti44 MRI2 P02 LNIV1
TiSR MRI2 B773 LNIV1
KH3J LNIV1 425 LNIV1
Tanl MRI2 B820/124 LNIV1
Tan8 MRI2 0512 LNIV1
N6 MRI2 BF138 LNIV1
M375 MRI2 B103 LNIV1
Afade MRI2 B345 LNIV1
Gladysdale MRI2
Rosario Gongalves, Laboratorio Nacional de Investigagao Veterinaria (LNTV), Lisboa, Portugal -
2John March, Moredun Research Institute (MRI), Penicuik, UnitedKingdom.
2.2.2. Monoclonal antibodies (mAbs).
MAbs 6D11, 3F10, 3H22, 6E4, 2A3, 1D3, 1E6 and 3H7 were supplied by H.
Ball (Department of Agriculture for Northern Ireland, Veterinary Sciences Division,
Belfast, Northern Ireland, United Kingdom). MAbs 1C9 and 1B9 were produced at
MRI (this thesis, section 2.2.5.). MAb PK2 was supplied by Sankale Shompole
(Kari, Kabete, Kenya, Africa). All the mAbs were of IgM isotype.
2.2.3. Anti-MmmSC bovine polyclonal sera.
Antiserum N28 was supplied by Willie Amanfu (National Veterinary
Laboratory, Gaborone, Botswana) and came from an unvaccinated, naturally infected
cow (Botswana, 1996). Antiserum PP34 was supplied by Benedict Lema (Animal
Diseases Research Institute, Dar-es-Salaam, Tanzania) and came from an
unvaccinated, naturally infected cow (Pawaga, Tanzania, 1997). Antiserum 5754 was
supplied by J. Habyarimana (Veterinary Diagnostic and Epidemiology Laboratory,
Entebbe, Uganda) and came from a mixed-Zebu breed animal, vaccinated
subcutaneously with MmmSC vaccine strain Tj44. Antiserum 125 was supplied by
Bakary Cisse (Laboratoire de Production Animale, Bingeville, Ivory Coast) and
came from a Holstein-breed animal, vaccinated in the tail tip with MmmSC vaccine
strain TiSR. Antisera from bulls 180 and 184 were from a trial performed in Kenya
with local breeds of Kenyan cattle vaccinated subcutaneously with MmmSC vaccine
strain TiSR.
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2.2.4. Anti-bovine lung mouse sera.
Six 12-week-old female Balb/c mice were immunised with 100 jal of lung
homogenate (section 2.3.1.) diluted with an equal volume of Montanide ISA 206
(Seppic) injected subcutaneously to each mouse on day 0 and day 21. Mice were bled
on day 28.
2.2.5. Production of monoclonal antibodies.
Five 8-12 week old female Balb/c mice were injected with 100 pi each
(equivalent to 50 pg) of a mixture of a membrane fraction from mycoplasma strains
TiSR, V5 and B820/124 after fractionation with Triton XI14 (Sigma, X-114)
(section 2.2.6.), diluted with an equal volume of Montanide ISA 206 (Seppic). The
injections were made subcutaneously, at day 0, day 21 and day 42. On day 50, mice
were boosted with 100 pi (equivalent to 50 pg) of the antigen, without adjuvant,
intraperitoneally. The mouse with the highest anti-capsular polysaccharide (CPS)
antibody titre (measured by ELISA, section 2.4.2.) was killed 3 days later and the
spleen was removed and placed in RPMI 1640 medium (RPMI) (produced at the
Faculty of Veterinary Medicine (FVM), Edinburgh, United Kingdom). NSO
myeloma cells (obtained from Deborah Allen, Department of Veterinary Pathology,
FVM, Edinburgh, United Kingdom) were centrifuged 3 times with RPMI without
foetal calf serum (FCS) at 420 g for 5 min. A single cell suspension from the spleen
was made and spun 3 times with RPMI with 1% 200 mM L-glutamine solution (v/v)
(L-glu) (Life technologies, 25030-024) and 1% 50 mM 2-mercaptoethanol solution
(v/v) (ME) (Life technologies, 31350-010) at 420 g for 5 min. Polyethylene glycol
1500 (PEG 1500) (50% PEG 1500 (w/v) in 75 mM HEPES, pH 8.0, Boehringer
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Mannheim, 783641) was heated at 37°C. The spleen and NSO cells were mixed and
spun at 270 g for 5 min. The supernatant was removed and the tube containing the
pellet was placed in a water bath at 37°C. One ml ofPEG 1500 was added to the cell
pellet over a period of 1 min while the cells were continually stirred with a pipette in
the water bath at 37°C. The cells were stirred for a further 1 min. Fifteen ml ofRPM3
with L-glu and ME, pre-warmed at 37°C, was added over a period of 3 min while
stirring the cells. The cell solution was incubated for 6 min at 37°C then spun at
100 g for 5 min. The supernatant was removed and the cells were resuspended in
RPMI with 20% FCS (PAA Laboratories, A15-326), L-glu, ME, 2% 5 mM
hypoxanthine-20 pM aminopterin-0.8 mM thymidine solution (v/v) (HAT) (Life
technologies, 21060-017) and 1% 100 mM sodium pyruvate solution (v/v) (Life
technologies, 11360-039) to give a final cell density of 106 NSO cells/ml.
One hundred pl/well of this cell suspension was plated out in 96-well cell culture
plates (Corning incorporated, 3595) that already contained 100 pl/well of mixed
thymocyte medium (section 2.2.7.). The plates were incubated at 37°C with 5% CO2.
The supernatants from the wells were checked, using an en2yme linked
immunosorbent assay (ELISA) (section 2.4.1.), to identify the positive wells against
MmmSC CPS. The positive hybridomas were cloned on agar plates, made with
400 ml ofRPMI containing L-glu, ME, HAT and sodium pyruvate mixed with 50 ml
of 5% agar solution (Difco, 214010). The agar solution was melted then cooled down
to 45°C; RPMI with L-glu, ME, HAT and sodium pyruvate was warmed to 45°C.
Positive hybridomas were diluted from 105 to 102 cells/ml. Two ml of the previous
cell dilution was mixed with the same volume of the medium used to make agar
plates. Two ml of this mixture was poured on the agar plates. Plates were incubated
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at 37°C with 5% CO2 for a week. Individual colonies were picked out with a Pasteur
pipette and placed in 24-well cell culture plates (Corning incorporated, 3524) with
RPMI with L-glu, ME, HAT and sodium pyruvate. The clones were checked for their
specificity againstMmmSC CPS by ELISA (section 2.4.1.).
2.2.6. Triton XI14 fractionation ofMmmSC.
Three grammes of MmmSC strains were mixed, in a chilled tube, with
154 mM NaCl (Fisher scientific, S/3160/60) lOmM Tris (Sigma, T-1503) solution
(TS), pH 7.4 containing 100 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma, P-
7626), stored at 4°C, to have a final volume equal to 9 ml. One ml of 10% Triton
XI14 (Sigma, X-114) solution (TX114), kept at 4°C, was added. The mixture was
vortexed then shaken at 4°C for 2 h. The tube was centrifuged at 12,000 g for 5 min
at 4°C. The supernatant was placed in a water bath at 37°C for 5 min then
centrifuged at 8,000 g for 3 min at 25°C. The lower (TX) phase was chilled on ice
then mixed with 9 ml of TS-PMSF, vortexed, placed for 3 min on ice, incubated for
5 min at 37°C then centrifuged at 8,000 g for 3 min at 25°C. The TX phase was
saved and the previous procedure was repeated 3 times. The last TX phase obtained
was stored at - 80°C. To remove the detergent, 9 volumes ofmethanol at 4°C were
added and mixed to the solution then placed at - 80°C overnight. The sample was
centrifuged at 12,000 g for 10 min at 4°C and the methanol completely removed. The
pellet was resuspended in sterile phosphate buffered saline (PBS).
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2.2.7. Mixed thymocyte medium.
Thymus from two 6-week-old female Sprague rats and two 6-week-old
female Wistar rats were taken aseptically, put in tubes containing Hanks' balanced
salt solution (produced at the Department ofVeterinary Pathology, FVM, Edinburgh,
United Kingdom). The thymuses were cut separately into pieces and placed in tubes
with RPMI with 1% L-glu (Life technologies, 25030-024) and 1% 10,000 units/ml
penicillin 10,000 pg/ml streptomycin solution (PS) (Life technologies, 15140-122)
pre-warmed at 37°C. The cell suspensions were pooled and centrifuged at 400 g for
5 min. The supernatants were discarded and the pellets were resuspended in 40 ml
RPMI with L-glu and PS. The tubes were spun at 400 g for 5 min. This operation
was repeated 3 times. Then, the cells were mixed with 200 ml of RPMI with 15%
FCS (PAA Laboratories, A15-326), L-glu and PS to give a final cell density of
4.5xl06 cells/ml and placed in tissue culture flasks (Nunc, 178905). The flasks were
incubated at 37°C with 5% CO2 for 2 days. The cell suspension was centrifuged at
850 g for 10 min at 4°C. The supernatant was filtered-sterilised, aliquoted under
40 ml and frozen at - 80°C.
2.2.8. Immunoglobulin (Ig) M purification.
One litre of 3F10 cell culture supernatant was concentrated to 8.7 ml by
centrifugation at 2,000 g using a centrifugal filter device (Millipore Ultrafree-15 with
Biomax-50K membrane, Sigma, Z36,465,7) then stored at 4°C. An IgM affinity
column (ImmunoPure immobilized mannan binding protein, Pierce, 1855580), stored
at 4°C, was placed at room temperature and prewashed with 5 ml of column
preparation buffer (ImmunoPure mannan binding protein preparation buffer, Pierce,
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21018) at room temperature. The column was placed at 4°C then equilibrated with
20 ml of cold binding buffer (CBB) (ImmunoPure IgM binding buffer, Pierce,
21016) kept at 4°C. Cold mAb 3F10 was diluted with the same volume ofCBB. The
column was filled with a part of the sample, then capped at the bottom and incubated
for 30 min at 4°C. The column was then opened and the second part of the sample
was allowed to enter completely the gel (while the first part passed through the
column). Five hundred pi ofCBB were added. The column was capped at the bottom
and incubated overnight at 4°C. After incubation, still at 4°C, the column was
washed with 42 ml of CBB. The column was removed from the cold and 3 ml of
elution buffer (ImmunoPure IgM elution buffer, Pierce, 21017) kept at room
temperature was added. The column was capped at the bottom and incubated at room
temperature for 1 h. Forty-two ml of elution buffer at room temperature was added
and the eluate was collected in 3 ml fractions. The elution of IgM was monitored
using absorbance readings at 280 nm. Fractions with absorbances above or equal to
0.02 were pooled then dialysed against PBS. The concentration of protein was
assessed by Pierce protein assay (Pierce, 23223 and 23224). The purity was checked
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
western-blot (WB) using anti-mouse IgM antibody (Serotec, STAR86P).
2.2.9. Labelling of monoclonal antibody and ascitic fluids.
Five mg of horseradish peroxidase (HRP) (Roche, 108090) was dissolved in
1.2 ml of distilled water (DW). Three hundred pi of freshly prepared 0.1 M sodium
periodate solution (Sigma, S-1878) in 10 mM sodium phosphate (Sigma, S-7907),
pH 7, was mixed with the HRP solution. The mixture was then incubated at room
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temperature for 20 min then dialysed against 1 mM sodium acetate solution (BDH,
102363P) pH 4 at 4°C overnight with 3 changes. One ml of ascitic fluid or culture
supernatant ofmonoclonal antibody secreting cells was mixed with the HRP solution
and incubated for 2 h at room temperature. One hundred pi of sodium borohydride
(Sigma, S-9125) at 4 pg/ml in DW was added and the solution was incubated for 2 h
at 4°C. The solution was then dialysed against PBS overnight with 3 changes.
2.3. Antigen preparation.
2.3.1. Bovine lung homogenate.
Normal bovine lung was cut into small pieces and placed in tubes (Ribolyser
Kit Red, Hybaid) containing glass beads and 10 mM Tris (Sigma, T-1503)-l mM
EDTA (Sigma, E-5134) buffer, pH 7.5. The tubes were shaken using a Hybaid
ribolyser at speed 6 for 2 min. The tubes were put in ice to cool them down, then
centrifiiged. The supernatants were kept at - 20 °C.
2.3.2. Galactan extraction from lung homogenate.
A fraction of lung homogenate (2.4 ml) was extracted 4 times with phenol-
chloroform-isoamyl alcohol (25:24:1) (Fisher scientific, BPE1752I-400) and once
with chloroform (Fisher scientific, C/4960/17), then precipitated with 9.6 ml of




Two hundred ml of supernatant from MmmSC strains grown in GB or CM,
containing 0.05% of sodium azide (Sigma, S-2002) were adjusted to pH 5 with
chlorhydric acid (BDH, 18036 5D) and autoclaved at 100°C for 30 min. The solution
was then centrifuged at 15,600 g for 15 min. Two volumes of ethanol (Fisher
scientific, E/0650DF/17) were mixed with the supernatant and the mixture was kept
at 4°C for 5 days to precipitate. The precipitate was resuspended with 20 ml ofDW
and centrifuged at 15,600 g for 10 min. The pellet was resuspended with 10 ml of
DW. One hundred pg ofDNAse I and II (Sigma, D-5025 and D-4138) and of 100 pg
of RNAse A and B (Sigma, R-5125 and R-7884) were added. The tube was
incubated in a water bath at 37°C for 18 h. Sodium dodecyl sulphate (SDS) (Sigma,
L-4509) was then added to a final concentration of 0.05%. One hundred pg of
proteinase K (Sigma, P-2308) was added and the solution was incubated in a water
bath at 45°C for 24 h. The solution was then dialysed in a 12-kDa dialysis tube
(Sigma, D-9652) against running tap water for 4 days. The dialysates were mixed
with 1 volume of phenol-chloroform-isoamyl alcohol (25:24:1) (Fisher Scientific,
BPE17521-400) and centrifuged at 1,600 g for 30 min. The upper (aqueous) phase
was removed, and to this was added 1 volume of chloroform (Fisher Scientific,
C/4960/17), well mixed and then centrifuged at 1,600 g for 30 min. The upper phase
was removed, and to this were added 3 volumes of ethanol. The tube was centrifuged
at 1,600 g for 30 min. The pellet was resuspended with 5 ml of 80% ethanol solution
then centrifuged at 1,600 g for 30 min. The supernatant was discarded and the pellet
was dissolved with 1 ml ofDW then spun at 21,000 g for 3 min. The supernatant was
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dialysed against running tap water for 5 h then against DW overnight. The dialysate
was spun at 21,000 g for 2 min. The supernatant was then stored at - 20°C.
2.3.4. Chromatography.
2.3.4.1. Chromatography on PD10 column.
The PD10 column (Pharmacia, 17-0851-01) was equilibrated with 25 ml of
DW (because the CPS used was in DW). A volume of 2.5 ml of CPS solution
purified from MrmrtSC strain V5 was added to the column. Twenty-five ml of DW
were then added to the column. The eluates were collected under 500 pi fractions in
Eppendorf tubes, straight after the addition of the CPS solution to the column. The
fractions were checked by SDS-PAGE followed by staining with Coomassie Blue
and SchifFs reagent.
2.3.4.2. Chromatography on G50 microcolumn.
CPS from Gemu Goffa and P02 were precipitated with 4 volumes of ethanol.
The pellets were resuspended in 50 pi of 1% ME (Sigma, M-3148) STE buffer (see
Appendices). The G50 microcolumn (Pharmacia, 27-5335-01) was vortexed to
resuspend the resin, then placed into a 1.5 ml Eppendorf tube and centrifuged for 1
min at 750 g. The samples were applied on the resin and centrifuged at 750 g for 2
min. The eluates were collected in 1.5 ml Eppendorf tubes. The column was washed
9 times with 100 pi of 1% ME-STE buffer by centrifugation at 750 g for 2 min. The
eluates from each wash were set aside. The first 7 eluates from the two samples were
used in an SDS-PAGE followed by Schiffs reagent staining and Silver staining.
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2.3.5. Carbohydrate concentration of purified CPS.
D-glucose (Sigma, G-6152) was used as a standard and diluted in PBS from
200 pg/ml to 3.125 pg/ml. The solutions of purified CPS were diluted in PBS (1:1,
1:3 and 1:7). Twenty-five pi of each solution was put in triplicate in 96-well plates
(Greiner, 655061). Twenty-five pi of a 5% phenol (Fisher Scientific, P/2315/PB17)
solution was added; the plates were mixed for 30 s then placed on ice. One hundred
and twenty-five pi of concentrated H2SO4 (Fisons, S/9240/PB17) was added to the
wells. The plates were shaken for 30 s then incubated in a water bath at 80°C for
30 min. The OD was measured at 492 nm.
2.3.6. Protein concentration of purified CPS.
Bovine serum albumin (Sigma, A-4503) was used as a standard. It was
diluted in PBS from 2,000 pg/ml to 1.953 pg/ml. The solutions of purified CPS were
diluted in PBS (1:1, 1:3 and 1:7). Twenty-five pi of each solution was put in
triplicate in 96-well plates (Greiner, 655061). Two hundred pi of protein assay
reagent (Pierce, 23223 and 23224) was added to each well. The plates were
incubated in a water bath at 37°C for 30 min. The OD was then measured at 540 nm.
2.3.7. Cereal extraction.
Three hundred mg of corn flour, oatmeal, rice, wheat semolina and wheat
flour were mixed in 15 ml ofDW and boiled for 30 min. The solutions were left for a
week at 4°C. Ten ml ofDW was added then the solutions were sonicated for 2 min.
They were spun at 4,800 g for 10-30 min. Two hundred and fifty pg of proteinase K
(Sigma, P-2308) was added to the supematants. The solutions were incubated at
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37°C for 5 days. The solutions were then placed at 4°C then pelleted. The
supernatants were removed stored in 1.5 ml Eppendorfs at 4°C.
2.3.8. Sonicated mycoplasmas.
One ml of mycoplasma culture (5x109 cells/ml) containing sodium azide at
0.05% (Sigma, S-2002) was centrifuged at 21,000 g for 5 min. The pellet was
resuspended in 1 ml of PBS then the mixture was spun at 21,000 g for 5 min. The
pellet was resuspended in 1 ml of 0.05% Tween 20 (Sigma, P-2287) in PBS (PBST)
then the solution was sonicated (Jencons Ultrasonic processor) by pulsation (50%
duty cycle) with the intensity sets on 2-3 for 60 s.
2.4. Immunoassays.
2.4.1. ELISA.
Plates (Greiner, 655061) were coated with 100 pl/well, in triplicate, of
antigen (CPS at 5 pg/ml in PBS or sonicated mycoplasma diluted 1/100 in PBS) and
incubated overnight at 4°C. They were washed 3 times with PBST then blocked with
100 pl/well of blocking reagent (BR) for 1 h at 37°C. After 3 washes with PBST,
plates were incubated with 100 pi/well of primary antisera diluted in BR, for 1 h at
37°C. The plates were washed 3 times. One hundred pl/well of specific HRP-
conjugated secondary antibody diluted in BR were incubated in the plates for 1 h at
37°C. After 3 washes with PBST, 100 gl/well of H2O2-0 phenylenediamine (OPD)
(1 tablet of each dissolved in 20 ml of DW) (Sigma, P-9187) was added and
incubated for 10 min at room temperature in the dark. The reaction was stopped by
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the addition of 50 pl/well of 3 M H2SO4 solution (Fisher scientific, S/9240/PB17)
then the OD was read at 492 nm.
Primary antibodies were:
- sera from intubated, vaccinated and in-contact cows with MmmSC diluted
1/5,000;
- undiluted hybridoma supernatants;
- mAbs diluted 1/400 for isotyping;
- mAbs diluted 1/100 (1E6, 3H7), 1/400 (1C9, 1D3, 1B9), 1/1,000 (2A3) and
1/2,000 (PK2, 6D11, 3F10, 3HI2, 6E4) to look at CPS epitopes onMmmSC strains;
- mAbs diluted 1/25,000 (3H12), 1/100 (2A3), 1/50,000 (3F10), 1/12,500
(6E4, 6D11), and 1/800 (PK2) to look at CPS epitopes on Mycoplasma mycoides
subspecies mycoides LC and Mycoplasma mycoides subspecies capri strains.
HRP-conjugated secondary antibodies were:
- anti-cow IgM antibody (Serotec, AAI19P) diluted 1/1,000, anti-cow IgA
antibody (Serotec, AAI20P) diluted 1/1,000, anti-cow IgG antibody (Serotec,
AAI23P) diluted 1/50,000;
- anti-mouse immunoglobulin antibody (Dako, P0447) diluted 1/2,000, anti-
mouse isotype immunoglobulin antibodies (Serotec, STAR81P, STAR82P,
STAR83P, STAR84P, STAR85P and STAR86P specific for IgGi, IgG2a, IgG2b,
IgGb, IgA and IgM respectively), diluted 1/5,000.
2.4.2. Titration ELISA.
The plates (Greiner, 655061) were coated with 50 pi/well of 5 pg/ml of pure
CPS from MmmSC strain P02, diluted in PBS, for 2 h at room temperature. They
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were rinsed 3 times with PBST, and then incubated with 50 pl/well ofBR for 1 h at
37°C. After 3 rinses with PBST, 50 jal/well of each antiserum diluted from 1/50 to
1/819,200 in BR was added. The plates were incubated for 1 h at 37°C. The plates
were rinsed 3 times and incubated with 50 pi/well of HRP-conjugated anti-rabbit
immunoglobulin antibody (Dako, P0448) diluted 1/2,000 in BR. After 3 rinses with
PBST, plates were developed with H2O2-OPD (Sigma, P-9187) as described in
section 2.4.1. but with an incubation time of 15 min instead of 10 min. A line was
drawn from the linear part of the curve and the titre was the intersection point
between this line and the x-axis.
2.4.3. Competitive ELISA.
Plates (Greiner, 655061) were coated with 50 pl/well of CPS from P02
grown in CM, diluted at 5 pg/ ml in PBS and incubated overnight at 4°C. They were
washed 3 times with PBST, and then blocked with 50 pl/well with BR for 1 h at
37°C. After 3 washes with PBST, 50 pl/well of unconjugated mAbs (3H10, 3H12,
6D11, 6E4 and PK2), serially diluted from 1/50 to 1/104,857,600 in BR, were added,
in duplicate, to the plates and incubated for 1 h at 37°C. Plates were washed 3 times
with PBST. The conjugated mAbs (3F10, 3H12, 6D11, 6E4 and PK2, respectively
diluted 1/32,000, 1/500, 1/10,000, 1/1,600 and 1/50 in BR) and the anti-mouse
immunoglobulin antibody-HRP (Dako, P0447), diluted 1/2,000 in BR, 50 pl/well,
were incubated for 1 h at 37°C (the conjugated anti-mouse immunoglobulin antibody
was used to detect the signal from the unconjugated mAbs). After 3 rinses with
PBST, plates were developed with H2O2-OPD (Sigma, P-9187) as described in
section 2.4.1. but with an incubation time of 12 min instead of 10 min.
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2.5.Western-blots.
Antigens were diluted with an equal volume of loading buffer (LB) and
loaded on a single large well 12.5% SDS gel (see Appendices) using a Mini Protean
II module (Bio-Rad, 165-2944). The gels were run at 100 V then transferred onto
nitrocellulose membranes (Amersham, RPN203E) for 45 min to 1 h at 300 rnA using
Trans-Blot SD semi-dry transfer cell (Bio-Rad, 170-3949). The membranes were
stained overnight in Ponceau Red (Sigma, P-3504) staining solution (see
Appendices). After destaining (see Ponceau Red destain in Appendices) until no
staining background was visible, the membranes were rinsed in DW for 10 min. The
membranes were incubated in BR for 1 h at room temperature, under agitation. For
the next steps, a Mini-Protean II Multiscreen was used (Bio-Rad, 170-4017). The
sheets were rinsed 3 times in PBST. Primary antibodies were diluted 1/400 in BR
and incubated with the membranes at room temperature for 1 h 30 under agitation.
Primary antibodies were removed and the membranes were rinsed 3 times with
PBST. The secondary antibodies conjugated to HRP specific for the primary
antibody were diluted 1/400 in BR and incubated at room temperature for 1 h 30
under agitation. After 3 rinses with PBST, the substrate, 50 pi of H2O2 (Sigma, H-
1009) and few grains of diaminobenzidine (Sigma, D-5637) in 100 ml ofPBST, was
added and left for 10 min. The reaction was stopped by rinsing the membrane with
DW.
Antigens were:
- 100 pi of each cereal extract and 100 pi ofpurified CPS (1.08 mg/ml) from
MmmSC strain V5 grown in CM;
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- 225 (J.1 of lung homogenate, boiled for 3 min and spun at 21,000 g for 3 min,
lung extract and 1 ml (803 pg/ml) of purified CPS fromMmmSC strain Afade grown
in CM, precipitated with ethanol and resuspended in 200 pi ofLB;
- 100 pi of purified CPS (1.08 mg/ml) from MmmSC strain V5 grown in CM
and 100 pi of lung homogenate.
Primary antibodies were pre-immune cow sera, anti-M/wwSC cow sera, anti-
MmmSC rabbit sera, mAbs, and anti-bovine lung mouse sera.
HRP-conjugated secondary antibodies were anti-cow immunoglobulin
antibody (Dako, P0159), anti-rabbit immunoglobulin antibody (Dako, P0448) and
anti-mouse immunoglobulin antibody (Dako, P0447).
2.6. Western-blot adherence assay.
Preparation of the membrane:
Strains ofMmmSC were pelleted by centrifugation at 21,000 g for 5 min. The
pellets were resuspended in PBS and centrifiaged again at 21,000 g for 5 min. The
previous step was repeated another time. The pellets were then resuspended in LB
and boiled for 5 min, then centrifuged for 3 min at 21,000 g. The supernatants were
loaded onto a 12.5% SDS gel which was run overnight at 50 V and then transferred
onto a membrane (Immobilon-P, Millipore) at 300 mA for 1 h using Trans-Blot SD
semi-dry transfer cell (Bio-Rad, 170-3949). The membrane was stained overnight in
Ponceau Red (Sigma, P-3504) staining solution (see Appendices). Finally, the blot
membrane was destained and stored wet until use.
For the transfer, two sheets ofWhatman paper were soaked in Anode buffer I
(see Appendices), one sheet ofWhatman paper was soaked in Anode buffer II (see
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Appendices) and two sheets ofWhatman paper were soaked in Cathode buffer (see
Appendices). The membrane was incubated for 15 s in 100% methanol solution, then
soaked in DW for 2 min. The membrane was then put for 5 min in Anode buffer II.
The sheets of Whatman paper incubated in Anode buffer were placed under the
membrane covered with the gel; the sheets of Whatman paper incubated in Cathode
buffer were placed on top of the gel.
Preparation of the cells:
Two flasks of embryonic bovine lung (EBL) cells, in 5 ml of minimum
essential medium Eagle (MEM) with 10% FCS and 50 pg/ml gentamicin (Sigma),
were incubated at 37°C and 5% CO2 for 18 h. Four pi (0.75 MBq) of 35S-methionine
(Amersham) were added in each flask. The cells were then incubated for 18 h at
37°C and 5% CO2. The culture medium was removed from the flasks. Cells were
quickly washed with 5 ml of PBS. Five hundred pi of 10X trypsin (Boehringer
Mannheim)-EDTA in 4.5 ml of DW were added to each flask which were shaken
gently for 1 min. About 90% of the liquid was removed. The flasks were agitated
until the cells dettached. Twenty pi of protease inhibitor (100 mM AEBSF) were
added to the flasks. The cells were then resuspended with 4 ml of Buffer A (see
Appendices).
Adherence assay:
The blot membrane was soaked in methanol then in DW. The membrane was
incubated in 20 ml of 2% skimmed milk powder in PBST for 1 h then rinsed twice
for 5 min with Buffer A. The membrane was incubated with EBL cells at 37°C for 4
h under agitation. The membrane was rinsed three times for 5 min with 20 ml of
PBST then put on Whatman paper to remove the rest of liquid on the membrane. The
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membrane was placed in a cassette for autoradiography for 4 days and then
developed.
2.7. Adherence inhibition assay in tissue-culture plates.
MmmSC strains N6 and M375 were inoculated in 200 ml of culture medium
with 60 pi of 3H-palmitic acid (Amersham) and incubated at 37°C until early log
phase. Mycoplasma bovis (M bovis) strain PG45 was used as a control. EBL cells
were cultured in 24-well plates (2.5xl05 cells/ml), in MEM with 10% FCS and
50pg/ml gentamicin (Sigma) for 20 h at 37°C and 5% CO2. The culture medium was
removed and 200 pi of 1% bovine serum albumin in Buffer A (see Appendices) were
added to each well. The plates were incubated under agitation at 37°C for 3 h.
Mycoplasmas were centrifuged at 10,000 g for 15 min. The pellets were washed with
50 ml of PBS and centrifuged again at 10,000 g for 15 min. The pellets of
mycoplasmas were resuspended with 2 ml of PBS and spun at 14,000 g for 10 min.
Mycoplasmas strains N6 and M375 were resuspended with 800 pi ofBuffer A, PG45
with 1,600 pi of Buffer A. Different volumes (275 pi, 125 pi and 30 pi, respectively
56.1 pg, 25.5 pg and 6.1 pg) of purified mAb 1C9 (directed against MmmSC CPS)
were added to the tubes with 100 pi ofMmmSC strain N6. Different volumes (20 pi,
14 pi and 10 pi, respectively 87 pg, 60.9 pg and 43.5 pg) ofmAb 4D7 (specific for
M. bovis) were added to the tubes with 100 pi of either MmmSC strain M375 orM.
bovis strain PG45. Each volume of both mAbs was previously diluted with Buffer A
to give a final volume of 300 pi. The mixtures of mAb-mycoplasma were incubated
at 4°C for 2 h. The culture medium was removed from the culture plates. The
different solutions of mycoplasmas were added to the corresponding wells. The
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plates were then incubated at 37°C for 30 min under agitation. The liquid was
removed with a pipette and the wells were washed twice with 500 pi of cold Buffer
A. Five hundred pi of 10% SDS solution in PBS were added to the wells. The plates
were sealed with a plastic film and incubated overnight under agitation at room
temperature. The content from each well was then transferred to liquid scintillation
counting (LSC) tubes and 10 ml ofLSC cocktail (Roth) were added to the tubes. The
p-irradiation was then measured.
2.8. Growth inhibition test (GIT).
Mycoplasma strains were diluted in GB to give equal colony densities when
cultured on GA. Ten ml of different mycoplasma solutions was put on GA in
100 mm square Petri dishes (Bibby sterilin, 109). The plates were left at room
temperature for 30 min then the excess of the mycoplasma solution was removed
with a pipette. The plates were left to dry for at least 5 minutes. Filter paper discs
(Mast diagnostics, BD0638W) impregnated with 15 pi of serum or mAb solution
were placed in contact with the mycoplasmas on agar plates. The plates were
incubated at 37°C in 5% CO2 for 3 to 4 days. The zone of clearance between the disc
and the mycoplasma culture was then measured under light microscopy.
2.9. Passive immunisation.
Twenty-four 8-week-old female Balb/c mice were divided into 3 groups: two
groups of 10 and one group of 4. Mice from the first group were injected with
200 pl/mouse of sterile PBS subcutaneously. Mice from the second group were
injected with 200 pl/mouse of mAb 3F10 (250 pg/ml in PBS), IgM specific for
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MmmSC CPS. Mice from the third group did not receive any injection. Six hours
later, mice were challenged with 500 gl/mouse of 108 N6 mycoplasmas/ml,
intraperitoneally. One drop of blood was collected from each mouse in a bijoux
containing 3 ml of GB, 100 pi of this solution was diluted in 900 pi of GB in
Eppendorfs. Bijoux and Eppendorfs were incubated at 37°C with 5% CO2 for a
week. Mice were bled on day 0 (prior to injection), 1, 2, 3, 4 and 7. The positive
results could be seen by the change of colour in bijoux and Eppendorfs, indicating
the presence ofmycoplasmas.
2.10. Staining protocols.
2.10.1. Coomassie Blue staining of proteins.
The gel is incubated in Coomassie Blue staining solution (see Appendices)
overnight at room temperature under agitation. The gel is then destained by soaking
in Coomassie Blue destain solution (see Appendices) until the gel becomes clear.
2.10.2. Silver staining of proteins
The gels were soaked three times for 10 min in 40% methanol (Fisher
Scientific, M/4000/17)-10% acetic acid (Fisher Scientific, A/0400/PB17) solution
then rinsed three times for 5 min with DW. They were put in silver equilibration
solution for 30 min (see Appendices). The gels were rinsed for 20 s with DW and
then, incubated in development solution (see Appendices) for 30 min. The gels were
placed in stop solution (see Appendices) for 5 min and rinsed three times for 5 min
with DW. The gels were put in reducer solution (see Appendices) for 30 s and rinsed
under running tap water for 1 min and three times in DW for 5 min.
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2.10.3. SchifPs reagent staining of carbohydrates.
The gel is incubated for 10 min in 40% methanol (Fisher Scientific,
M/4000/17)-10% acetic acid (Fisher Scientific, A/0360/PB17) solution. The gel is
then transferred in 1% periodic acid (Sigma, P-7875)-3% acetic acid (Fisher
Scientific, A/0360/PB17) solution for 20 min and rinsed for 5 min twice with DW.
Then, it is incubated overnight in SchifPs reagent (Sigma, S-5133). After 4 rinses of
5 min with DW, the gel is soaked in 10% glycerol solution (Sigma, G-6279).
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3. Results.
3.1. Purification of the capsular polysaccharide (CPS)
from Mycoplasma mycoides subspecies mycoides small
colony (MmmSC).
CPS was purified from culture supernatant of 22 MmmSC strains grown in
Gourlay's broth (GB) (see section 2.3.3.). The analysis of the purity of the different
CPS solutions was assessed by a SDS-PAGE. The stacking gel was stained with
Setoff's reagent (see section 2.10.3.) and the separating gel with Coomassie Blue
(see section 2.10 1.). The results are given in Fig. 1. CPS appears in pink on the top
of the gel. The different solutions of CPS contained also peptides as shown in blue
on the bottom of the gel. A band around 50 kDa was present in the solution from the
strain B773. The nature of this protein is not known.


















The presence of these peptides in the CPS solutions could have led to a
problem in EL1SA since they could have interfered with the adhesion of CPS in the
ELISA plates. The removal of these peptides was attempted by gel filtration
chromatography using a PD10 column (see section 2.3.4.1.) with a fractionation
range for globular proteins of 1,000-5,000 Da. As shown in Fig. 2, peptides (on the
right) were still present in the CPS fraction (CPS on the left).
















It was then decided to do another gel filtration chromatography with a G50
microcolumn with a bigger fractionation range (1,500-30,000 Da) (see section
2.3.4.2 ). These attempts proved unsuccessful as the eluates containing CPS (top
gels) also contained peptides (bottom gels) (Fig. 3.).
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Fig. 3. SDS-PAGE of CPS solutions from MmmSC strains P02 and Gemu Goffa
after chromatography on G50 microcolumn.
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The different attempts to remove the peptides from purified MmmSC CPS
solutions did not work. A western-blot with CPS solutions from different MmmSC
strains was performed, using rabbit anti-M»w?SC strain N6 serum. The antiserum did
not recognise the peptides present in the different solutions of CPS, while showing a
signal against CPS, as shown in Fig. 4.
Fig. 4. Western-blot of CPS solutions from different strains ofMmmSC with rabbit





















Since the peptides were not recognised by the antiserum and that the use of
CPS in ELISA would not be quantitative but qualitative (i.e. it would not be the
quantity of CPS that would be detected but the presence or absence of epitopes on
this CPS) it was decided to use the CPS solutions with no further purification
procedures.
The use of these solutions in ELISA along with solutions from purified GB
(according to the same protocol as the purified MmmSC CPS solutions, used as a
negative control) showed that a component present in GB was recognised by antisera
directed against MmmSC (Fig. 5 and 6). It was then necessary to identify this
contaminant to prevent false positive reactions from CPS solutions. Firstly, it was
thought that the reaction was due to the yeast present in the composition of the
culture medium, but an ELISA, with a solution of yeast only along a solution of CPS
purified from culture supernatant ofMmmSC strain Afade and carbohydrate solution
purified from GB, proved that this component was not responsible for the reaction
(Fig. 5) since the serum raised against MmmSC strain N6 did not give any signal
against the yeast.











CPS from Afadd MDC yeast
samples
MDC: medium-derived carbohydrate, purified from GB
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The same experiment was performed with Bactotryptose, another component
of GB, and monoclonal antibodies (mAbs) against MmmSC CPS (Fig. 6). MAbs that
recognised carbohydrates from GB also exhibited a signal against carbohydrates
from Bactotryptose, suggesting that this was the component responsible for the false
positive reactions. Casein was subsequently used to replace Bactotryptose in the
MmmSC culture medium since it appeared that MmmSC strains grew similarly in
casein medium and GB and that this medium did not contain a carbohydrate that
would be recognised by sera raised againstMmmSC [Emma waite, personal communication].
Fig. 6. Recognition of different carbohydrate solutions purified from MmmSC strain









■ CHS CD MUG □ BUG
CPS: purified from MmmSC strain Afade, MDC: medium-derived carbohydrate purified from GB,
BDC: Bactotryptosc-dcrived carbohydrate purified from Bactotryptose.
3.2. Production of monoclonal antibodies (mAbs)
againstMmmSC CPS.
The investigation of the epitopes of CPS from different MmmSC strains was
performed using polyclonal sera (see section 3.3.) and monoclonal antibodies (see
section 3.2.).
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The production of mAbs was undertaken using spleen cells from mice
immunised with a membrane fraction of MmmSC (see section 2.2.6.) fused with
NSO cells (see section 2.2.5.). After the fusion, hybridomas were cultured in 96-well
culture plates. Hybridomas which supernatants gave a positive signal in ELISA
against whole mycoplasmas (Table 3) or MmmSC CPS (Table 4) were frozen in
liquid nitrogen.
Table 3. Scheme of 96-well culture plates containing hybridomas with results of
ELISA against whole mycoplasmas, MmmSC strains TiSR, V5 and B820/124.
1 2 3 4 5 6 7 8 9 10 11 12
1A
IB 3.894 1.204 1.287 3.231 1.098 1.953 3.920 3.640 3.714 1.185
1C 3.911 1.340 3.500 1.567 1.510 1.277 3.879 3.559 1.228 3.253
ID 3.437 1.605 1.013 1.378 1.583 3.903 1.952 1.139 3.665 1.707
IE 3.840 1.591 0.956 0.779 1.002 1.297 1.442 3.718 1.388 3.688
IF 3.672 1.630 1.270 1.666 2.149 3.631 1.150 1.582 1.153 3.029
1G 3.683 0.985 1.624 1.892 1.017 1.735 0.921 1.066 1.058 1.277
1H
1 2 3 4 5 6 7 8 9 10 11 12
2A
2B 1.058 1.223 2.188 3.748 1.428 1.486 1.328 3.803 3.756
2C 1.660 3.088 1.097 0.897 1.216 1.147 1.045 3.604 3.713
2D 0.951 1.745 2.157 3.617 1.222 1.224 1.533 1.828 3.749
2E 1.201 1.222 1.225 1.653 2.468 1.075 1.158 0.827 3.592
2F 1.438 1.906 1.742 3.686 1.249 1.338 3.623 1.221 3.572
2G 0.945 3.722 3.445 1.017 1.262 1.335 1.175
2H
data: results from ELISA at OD 492 rnn, cells with bold
cells, data in bold: hybridomas to be frozen.
>orders: wells containing unfusioned spleen
Attempts to clone these hybridomas on agar plates were made several times
for most of them. Unfortunately, problems occurred in the process including the
contamination of the cultures by fungi or bacteria. When the problem of
contamination was solved, it appeared that the hybridomas were not in a healthy state
after thawing as they did not multiply but died.
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Table 4. Scheme of 96-well culture plates containing hybridomas with results of
ELISA against CPS fromMm/wSC strains TiSR, V5 and B820/124.
1 2 3 4 5 6 7 8 9 10 11 12
1A
IB 0.376 0.185 0.170 1.560 0.065 0.915 3.473 3.588 3.608 0.075
1C 0.297 0.074 2.755 0.078 0.089 0.157 3.461 3.566 0.072 1.395
ID 0.651 0.080 0.062 0.094 0.071 3.272 0.071 0.419 3.329 0.068
IE 0.269 0.064 0.066 0.064 0.078 0.108 0.313 3.112 0.083 3.326
IF 0.301 0.064 0.025 0.051 0.042 3.370 0.021 0.303 0.024 1.980
1G 0.438 0.069 0.051 0.240 0.070 0.078 0.052 0.060 0.057 0.054
1H
1 2 3 4 5 6 7 8 9 10 11 12
2A
2B 0.079 0.223 0.092 2.712 0.064 0.059 0.061 2.650 0.603
2C 0.078 1.622 0.069 0.065 0.107 0.073 0.070 2.904 0.463
2D 0.067 0.067 0.542 2.303 0.063 0.054 0.064 0.053 0.659
2E 0.060 0.062 0.087 0.079 0.191 0.055 0.074 0.049 0.559
2F 0.037 0.448 0.171 2.217 0.031 0.030 2.828 0.289 0.450
2G 0.056 2.726 2.493 0.062 0.057 0.058 0.056
2H
data: results from ELISA at OD 492 nm, cells with bold borders: wells containing unfusioned spleen
cells, data in bold: hybridomas to be frozen.
Five hybridomas, 1B5, 1B8, 1B9, 1C9 and 1E11, were finally cloned. For
two of them (clones from hybridomas 1B5 and 1B8), no antibodies specific for CPS
appeared to be present in the culture supernatants when tested by ELISA (Fig. 7).









antigen used: purified CPS (fromMmmSC strain Tan8 for mAbs 1B5, 1B8 and 1B9, and from mixed
MmmSC strains T1SR, V5 and B820/124 for mAbs 1C9 and 1E11), the mAbs came from undiluted
cell culture supernatants.
1B5 1B8 1B9 1C9 1E11
monoclonal antibodies
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The antibody titre against CPS for the three mAbs that recognised CPS (1B9,
1C9 and IE 11) was very low after subculture, as measured by ELISA (Fig. 8). It
should be noted that these clones grew very slowly and consequently, it was difficult
to obtain a large amount of culture supernatants.
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dilution of mAb 1E11 (1 :x)
antigen used: purified CPS (fromMnmSC strain Tan8 for mAb 1B9, and from mixedMmmSC strains
T1SR, V5 and B820/124 for mAbs 1C9 and 1E11).
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All three mAbs 1B9, 1C9 and 1E11 were of IgM isotype (Fig. 9).












■ anti-lgA aanti-IgM Danti-lgG1 nanti-lgG2a □ anti-lgG2b nanti-lgG3
antigen used: purified CPS (fromMmmSC strain Tan8 for mAb 1B9, and from mixed MmmSC strains
T1SR, V5 and B820/124 for mAbs 1C9 and 1E11). box: anti-mouse immunoglobulin antibody.
The results are summarised in Table 5
Table 5. Summary of the production ofmAbs againstMmmSC CPS.
Hybridomas Anti-CPS Attempts Successful Remarks
antibodies of cloning cloning
1B5 Y 4u X Abs non specific for CPS
1B7 Y 4I/2
1B8 Y 51'2 X Abs non specific for CPS








1E9 Y 0 1,23

















Y: hybridomas producing anti-MwnSC CPS antibodies, N: hybridomas producing antibodies specific
forMmmSC (not against CPS), 1: contamination either by fungi or bacteria, 2: nomultiplication of tire
hybridomas after thawing and culture.
3.3. Growth inhibition test (GIT) with MmmSC strains
and rabbit polyclonal sera.
An efficient vaccine is one able to protect against a maximum, if not all,
strains of the microorganism. In previous studies, it was shown that antibodies
responsible for the inhibition in GIT were antibodies directed against CPS. When the
sera were pre-absorbed with CPS they did not exhibit growth-inhibiting activity
anymore [ii6]. The most virulent strains produce more CPS [no] and CPS has been
shown to have toxic effects in cattle when injected on its own in the absence of
mycoplasma [4,23]. Strains producing the most CPS are also more resistant to
inhibition by antisera in GIT: CPS seems like a good potential vaccine. However, for
a vaccine using MmmSC CPS, it was necessary to know if CPS was conserved
between all strains.
Twenty-two MmmSC strains were tested with 23 antisera. Each antiserum
was raised against one of the MmmSC strains, as a consequence each antiserum
contained antibodies specific for CPS of the strain it was raised against. If these
antibodies also recognised CPS from other strains, they should inhibit the growth of
these strains.
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Growth inhibiting activity is shown in Fig. 10. Results were divided
according to the anti-CPS antibody titre of the rabbit sera (measured as the dilution
factor of the serum where the line from the linear part of the titration curve crossed
the x-axis).
Fig. 10. GIT ofMmmSC strains with rabbit polyclonal sera.
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Results obtained with sera against MmmSC strains Tanl, Afade, M375 and Gladysdale do
not appear on the graph because no clearance zone could be seen with these antisera against
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MmmSC strains on the x axis, zone of clearance on tire y axis. l:x: anti-CPS antibody titre indicated
behind the serum ofwhich it applies.
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Fig. 10 (concluded). GIT ofMwwSC strains with rabbit polyclonal sera.










































□ anti-B773 1:50,000 es anti-B820/124 1:50,000
□ anti-0697 1:50,000
MmmSC strains
CPS serum titre >1:95,000
■ anti-N6 1:100,000 ~q anti-0512 1:100,000 "a anti-P02 1:100,000
□ anti-Gemu Goffa 1:200,000 D anti-Fiifili 1:200,000 e anti-B345 1:200,000
MmmSC strains on the x axis, zone of clearance on the y axis. 1 :x: anti-CPS antibody titre indicated
behind the serum ofwhich it applies.
For sera with a titre below 1:15,000 (Fig 10. A), none of the sera exhibited GI
activity apart from anti-425 and anti-6479 (these latter sera had only a small amount
of growth inhibiting activity). For sera with a titre between 1:15,000 and 1:45,000
(Fig. 10. B), some GI activity was seen, but against less than half of the strains. This
activity was low as the zone of clearance was mostly below 1 mm. For sera with a
titre between 1:45,000 and 1:95,000 (Fig. 10. C), the sera exhibited GI activity
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against 4 to 18 of the strains. The zones of clearance measured were mostly 1 mm or
above. Finally, most of the sera with a titre above 1:95,000 (Fig. 10. D) were
inhibitory. In this case, the zones of clearance observed were largely above 1 mm,
with many of them equal to or above 2 mm.
It is known the inhibition is due to antibodies against CPS present in the
serum as pre-absorbed antisera with CPS do not exhibit GI activity [ii6]. Serum raised
against any specific MmmSC strain contains antibodies against the CPS of this
specific strain. In the GIT, a specific antiserum not only inhibited the strain against
which it was raised, but also inhibited other strains. The activity of antisera was
related to the CPS-specific antibody titre and not to the strain they were raised
against. These findings suggest that epitopes responsible for GI activity are present
on all strains of MmmSC (i.e. CPS is probably conserved between strains).
Moreover, sera with the highest anti-CPS antibody titre exhibited the greatest GI
activity. However, some exceptions exist as it can be seen, for example, with anti-
425 serum (showing a low anti-CPS antibody titre but a marked GI activity) and with
anti-Filfili serum (a high CPS-specific antibody titre but a low GI activity). This
might be due to the nature of CPS-specific antibodies in the sera. Antibodies against
CPS might not be all involved in growth inhibition. In the case of anti-425 serum,
maybe the total amount of antibodies against CPS is low but most of them are
inhibiting. And for the anti-Filfili serum, the sera may contain a large amount of
antibodies specific for CPS but most of them may not be growth inhibiting. It cannot
be excluded that, for some strains, antibodies against other components of the
mycoplasma might have growth inhibiting activity as well.
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3.4. Analysis of CPS from mycoplasma strains with
mAbs.
Previous data (see section 3.3.) suggested CPS epitopes were shared between
all strains ofMmmSC. However, it cannot be excluded that some epitopes might be
present in only some of the strains. CPS was investigated using monoclonal
antibodies in order to see if strain-specific CPS epitopes existed.
3.4.1. Analysis ofMmmSC CPS.
Eleven mAbs (see Materials and methods, section 2.2.2) were tested by
ELISA against CPS purified from 22 individual strains ofMmmSC and from two
strains of Mycoplasma capricolum subsp. capripneumoniae (Mccp) (these
mycoplasma strains were grown in Gourlay's medium). Mccp is related to MmmSC,
causing a similar disease in goats (contagious caprine pleuropneumonia). Three
batches of Gourlay's medium derived carbohydrates (MDC), purified following the
same protocol as mycoplasma CPS, were also tested with the mAbs. MDC was used
as a control to be sure the signal observed from CPS solutions incubated with mAbs
was from CPS and not from a contaminating medium component. A high molecular
weight polymer was found in the culture medium (as shown on a SDS-PAGE stained
with SchifFs reagent), as a consequence it was present in solutions of purified
CPS [150],
All the monoclonals recognised CPS from the different MmmSC strains
(Fig. 11). In addition, 4 of them (boxed data) also reacted with CPS from Mccp
strains and with MDC, with a signal as high as the one observed with CPS from
MmmSC. It is unclear whether these mAbs recognised a common epitope present
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both on CPS and on the culture medium carbohydrate, or if they only recognised the
contaminating MDC. CPS from all the strains appeared to be recognised in the same
way with each of the antibodies except with mAbs PK2 and 2A3, which exhibited a
low signal with the CPS from the strain PG1. This was at a similar level as the
reaction with CPS from the Mccp strains and MDC suggested that this strain might
be antigenically different from the others concerning the epitope recognised by these
two mAbs.


































♦ CPS from MmmSC strains • MDC from broth a CPS from Mccp strains
Monoclonal antibodies on the x axis, OD on the y axis. CPS: capsular polysaccharide. MDC: medium
derived carbohydrate. MmmSC: Mycoplasma mycoides subsp. mycoides small colony. Mccp:
Mycoplasma capricolum subsp. capripneumoniae, broth: uninoculated mycoplasma culture medium.
Five monoclonals were tested in GIT with MmmSC strain Gemu Goffa to
look at their inhibiting activity. Monoclonals that had the highest titre in the previous
ELISA were chosen (see Materials and Methods section 2.4.1.). Gemu Goffa was
chosen because it showed a good sensitivity to inhibition by rabbit polyclonal
antisera raised against various MmmSC strains. All the monoclonals were growth
inhibiting (Table 6). It is not known if the bactericidal activity is related to the CPS-
specific antibody titre as no titration has been performed on these mAbs.
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Table 6, GI activity ofmonoclonal antibodies against MmmSC strain Gemu Goffa.






3.4.2. Analysis ofMycoplasma mycoides subspecies mycoides
large colony (MmmLC) and Mycoplasma mycoides subspecies capri
(Mmc) with anti-CPS monoclonal antibodies.
MmmLC and Mmc have high similarity according to 16S rRNA sequence
analysis and have the same tRNA profile [151,152]. These two species are classified in
the Mycoplasma mycoides subgroup along with MmmSC and can cause pneumonia
in goats. MmmLC has immunological similarities with MmmSC: for instance, anti-
MmmLC polyclonal sera are growth inhibiting for both MmmLC and MmmSC [153].
Assuming the inhibiting activity in anti-Mw/wLC sera is due to anti-CPS antibodies
as it has been shown in antisera raised against MmmSC, this suggests the CPS from
MmmSC and MmmLC could share common epitopes. In consequence, it was
interesting to investigate whether the epitopes on MmmSC CPS recognised by the
5 previous mAbs were also present on CPS from MmmLC and Mmc. MAbs were
used in ELISA (Fig. 12) against sonicated mycoplasmas and in GIT (Table 8) against
live mycoplasmas. The mycoplasma strains used are listed in Table 7. MmmSC strain
N6 was used as a positive control.
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Table 7. Mycoplasma strains used in Experiment 3,4.2.
Strains Species Strains Species
N61 MmmSC
UM308472 MmmLC 133/872 Mmc
<N00O MmmLC WK3542 Mmc
G102 MmmLC L2 Mmc
Y goat1 MmmLC PG31 Mmc
2/933 MmmLC BQT3 Mmc
247/43 MmmLC
53073 MmmLC
strains supplied by MRI, Penicuik, United Kingdom, 2strains supplied by Goran Bolske, Uppsala,
Sweden and 3strains supplied by Robin A.J. Nicholas, Addlestone, United Kingdom.
In the ELISA, as expected, N6 showed a signal with all the mAbs. MAb 3F10
gave a signal with MmmLC strains UM30847, G8, G10, Y goat and 2/93 and with
Mmc strains 133/87 and WK354 to the same intensity as the one observed with
MmmSC strain N6. The signal intensity for MmmLC strain 247/4 was half that
observed with the other strains. This could indicate that less CPS was present in the
cell extract used to coat the ELISA plate with this strain since the signal was less
high with all different mAbs when compared to the signal observed with the other
strains. MAb 6E4 recognised the same mycoplasma strains as 3F10, i.e. all MmmLC
strains apart 5037 and two Mmc strains 133/87 and WK354. MAb 6D11 showed a
signal with MmmLC strains UM30847, G10 and Y goat and with Mmc strain
WK354. MAbs 3H12 and PK2 did not show a good signal with any of the MmmLC
and Mmc strains when compared with N6. MmmLC strain 5307 and Mmc strains
PG3, BQT and L were not recognised by any of the monoclonals. These results are
summarised in Table 8, optical densities below 0.4 were considered as negative.
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13F10 □ 6E4 H6D11 D3H12 □ PK2
Mycoplasma strains on the x axis, OD at 492 nm on the y axis. MmmSC: Mycoplasma mycoides
subsp. mycoides small colony, MmmLC: Mycoplasma mycoides subsp. mycoides large colony, Mmc:
Mycoplasma mycoides subsp. capri
The previous mAbs used in the ELISA were then used in GIT (Table 8). They
were all bactericidal against MmmSC as previously tested against MmmSC strain
Gemu Goffa (see section 3.4.1., Table 6). MAbs 3F10 and 6E4 recognised epitopes
on MmmLC strains UM30847, G8, G10, Y goat, 2/93 and 247/4 and Mmc strains
133/87 and WK354 by ELISA. These mAbs were also growth inhibiting with all
these strains apart MmmLC strain G8 that showed no inhibition and MmmLC strain
2/93 which was inhibited only by 3F10. The growth inhibition is not affected only by
whether a strain exhibits an epitope on their CPS but also by the magnitude of CPS
production by a strain since a strain producing a lot CPS will be more resistant to
inhibition by CPS specific antibodies. The lack of inhibition of G8 and 2/93 might be
because they produce more CPS than the other strains and consequently do not show
inhibition of their growth. MAbs 6D11, 3H12 and PK2 did not exhibit any growth
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inhibiting activity against MmtnLC and Mmc strains this could suggest that
antibodies directed against CPS are not all bactericidal.
Table 8, Summary of the results ofELISA, GIT and LAT againstMmmLC andMmc.
Strains LAT
mAbs
3F10 6E4 6D1I 3H12 PK2
ELISA GIT ELISA GIT ELISA GIT ELISA GIT ELISA GIT
N61 + + nd4 + nd + nd + nd + nd
UM308472 + + 2 + 2 + 0 - 0 - 0
o00 to + + 0 + 0 - 0 - 0 - 0
G102 + + 2 + 2 + 0 - 0 - 0
Y goat2 + + 2 + 2 + 0 - 0 - 0
2/932 + + 2 + 0 - 0 - 0 - 0
247/42 - + 2 + 1.5 - 0 - 0 - 0
53072 - - 0 - 0 - 0 - 0 - 0
133/873 + + 2 + 2 - 0 - 0 - 0
WK3543 + + 2 + 2 + 0 - 0 - 0
L3 - - 0 - 0 - 0 - 0 - 0
PG33 - - 0 - 0 - 0 - 0 - 0
BQT3 - - 0 - 0 - 0 - 0 - 0
means agglutination and means no agglutination. ELISA: enzyme linked immunosorbent assay,
"+" means recognition of the mycoplasma strain by the mAb and no recognition of the
mycoplasma strain by the mAb. GIT: growth inhibition test, results expressed the clearance zone in
mm.
The results obtained in ELISA and GIT with MmmLC and Mmc strains are
summarised in a same table (Table 8) along with the results obtained with the same
strains in a latex agglutination test (LAT) [johnB. March, personal communication]. The LAT was
performed using latex beads coated with MmmSC CPS-specific rabbit IgG thus CPS-
positive strains agglutinated.
When the results are examined in respect of the mAbs, it seems that mAbs
can be classified in three categories. The first category contains antibodies 3F10 and
6E4 that bind to CPS in ELISA and show a growth inhibiting activity. The second
category concerns the antibody 6D11 that binds to CPS in ELISA but exhibits no
growth inhibiting activity. And finally the third category regroups antibodies 3H12
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and PK2 that show no signal with the CPS ofMmmLC and Mmc strains in ELISA
and no growth inhibiting activity. Since these mAbs are divided in three types, this
indicates that at least three different epitopes are recognised by these mAbs.
When the results are examined in respect of the mycoplasma strains, it seems
they can be divided in two groups. One group represents the strains recognised by the
mAbs, MmmLC strains UM30847, G8, G10, Y goat, 2/93 and 247/4 andMmc strains
133/87 and WK354. The other group contains the strains that are not recognised by
the mAbs, MmmLC strain 5307 and Mmc strains L, PG3 and BQT. These data fit
closely with the LAT data.
It has been suggested that according to their 16S rRNA sequence analysis and
tRNA profile, MmmLC and Mmc should be classified as the same species of
mycoplasma [151,1523. The results obtained with the monoclonals suggest that CPS of
MmmLC/Mmc exhibit at least two different serotypes. Further work is necessary to
obtain proper re-classification of the MmmLC and Mmc species. If these strains
represent a single mycoplasma species with two "serotypes", this is a novel finding
for mycoplasmas.
3.4.3. Competitive ELISA.
Previously (section 3.4.2.), it seemed that different CPS epitopes were
recognised by these 5 mAbs 3F10, 6E4, 6D11, 3H12 and PK2. To clarify the number
of epitopes recognised by these 5 mAbs, competition ELISAs were performed using
mAbs conjugated to horseradish peroxidase (HRP). Binding of each mAb to CPS
was competed against itself (i.e. for example, 3F10 with 3F10-HRP) as a positive
control to determine ifmAbs recognised the same or different epitopes.
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It was decided that at least three data points should also be under the
horizontal linear part of the curve to be considered as a drop in the curve.
The results obtained with unconjugated 3F10 in competition with various
HRP-conjugated mAbs are shown in Fig. 13. The graph obtained with 3F10 in
competition against itself is used as positive control (Fig. 13. A). Assuming equal
antibody concentration, mAb recognising the same epitope as 3F10 should give the
same curve as seen in Fig. 13. A. When 6E4-HRP (Fig. 13. B) was in competition
against unconjugated 3F10, a drop similar to the one observed on the graph with
3F10-HRP competing against 3F10 (Fig. 13. A) could be seen. The same results
were observed with unconjugated 3F10 in competition against 6D11-HRP
(Fig. 13. C), 3H12-HRP (Fig. 4. 13) and PK2-HRP (Fig. 13. E). According to these
graphs, all 5 mAbs seemed to compete equally against 3F10, and this would suggest
that they all recognise an identical epitope on CPS, unless a phenomenon of steric
hindrance occurs and prevent the binding of the mAbs.
The same conjugated mAbs were competed against unconjugated 6E4
(Fig. 14). As previously described for the mAb 3F10, the graph obtained with the
6E4 competing against 6E4-HRP (Fig. 14. A) was used for comparison with the
graphs obtained with the other conjugated mAbs in competition against unconjugated
6E4. No drop in the curve could be seen with 3FI0-HRP (Fig. 14. B), 6D11-HRP
(Fig. 14. C) and PK2-HRP (Fig. 14. E) suggesting 6E4 and 3F10, 6D11 and PK2 do
not recognise the same epitope on CPS.
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Fig. 13. Competitive ELISA between unconjugated 3F10 (dilution from 1/50 to
1/109) and HRP-conjugated 3F10, 6E4, 6D11, 3H12 and PK2 (constant dilution).
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incubation of 3F10 followed by incubation of HRP-conjugated anti-mouse secondaiy antibody,
incubation of 3F10 followed by incubation of HRP-conjugated mAb.
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Fig. 14. Competitive ELISA between unconjugated 6E4 (dilution from 1/50 to 1/109)
and HRP-conjugated 3F10, 6E4, 6D11, 3H12 and PK2 (constant dilution).
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The same procedure as before was followed with unconjugated 6D11; the
results with conjugated 6D11-HRP are shown on Fig. 15. A. No drop with 3F10-
HRP (Fig. 15. B) and a less marked drop with 6E4-HRP (Fig. 15. C) was observed
when put in competition against unconjugated 6D11, suggesting 3F10 and 6E4
recognise a different epitope on CPS than the one recognised by 6D11. The curves
from the competition ELISA of 3H12-HRP (Fig. 15. D) and PK2-HRP (Fig. 15. E)
against unconjugated 6D11 showed a clear drop indicating these three mAbs might
recognise the same epitope on CPS.
The curve of 3H12 in competition against itself, 3H12-HRP is shown on
Fig. 16. A. This curve was compared with the ones showing the competition of 3H12
against 3F10-HRP (Fig. 16. B), 6E4-HRP (Fig. 16. C), 6D11-HRP (Fig. 16. D) and
PK2-HRP (Fig. 16. E). None of the 4 mAbs showed a drop, suggesting these 4
monoclonals do not bind to the same epitope as 3H12.
MAb PK2 was put in competition against itself, conjugated to HRP
(Fig. 17. A). In contrast to the results observed with the other monoclonals in
competition against themselves, the curve obtained did not show a marked drop. As a
consequence, the results obtained from the competition of PK2 against the other
conjugated mAbs were dubious. No drop could be seen on the graph concerning the
competition of PK2 against 3F10-HRP (Fig. 17. B), 6E4-HRP (Fig. 17. C), 6D11-
HRP (Fig. 17. D) and 3H12-HRP (Fig. 17. E), suggesting they bound to a different
epitope onMmmSC CPS.
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Fig. 15. Competitive ELISA between unconjugated 6D11 (dilution from 1/50 to
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- ♦ incubation of 6D11 followed by incubation of HRP-conjugated anti-mouse secondary antibody,
incubation of 6D11 followed by incubation ofHRP-conjugated mAb.
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Fig. 16. Competitive ELISA between unconjugated 3H12 (dilution from 1/50 to
1/109) and HRP-conjugated 3F10, 6E4, 6D11, 3H12 and PK2 (constant dilution).
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incubation of 3H12 followed by incubation of HRP-conjugated anti-mouse secondary antibody,
incubation of 3H12 followed by incubation ofHRP-conjugated rnAb.
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Fig. 17. Competitive ELISA between unconjugated PK2 (dilution from 1/50 to 1/10 )
and HRP-conjugated 3F10, 6E4, 6D11, 3H12 and PK2 (constant dilution).
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incubation of PK2 followed by incubation ofHRP-conjugated mAb.
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The competition ELISA data are summarised in Table 9. Each mAb was
tested in competition against the other monoclonals, for example, unconjugated 3F10
against 6E4-HRP, then unconjugated 6E4 against 3F10-HRP. In the reciprocal
experiment, identical competition results should occur in each experiment, i.e. either
these mAbs recognise the same epitope on CPS and compete against each other in
both experiments or they bind to different epitopes and should not compete against
each other. As it is shown in Table 9, this was not observed.
For example, unconjugated 3F10 competing against 6E4-HRP (Fig. 13. B)
suggested these 2 mAbs bind to the same epitope on CPS (as indicated by a "+" in
the table).However, unconjugated 6E4 did not compete ("-" in the table) against
3F10-HRP (Fig. 14. B) suggesting the 2 mAbs bind to a different epitope. Such
contradictory results were not only obtained from the pair 3F10-6E4 but for most of
the pairs of mAbs competing against each other (see Table 9). Similar results were
obtained with the pairs 6E4-6D11, 6E4-PK2 and 3H12-PK2 where it seemed that
they recognised a different epitope onMwmSC CPS.
Table 9. Competitive ELISA between monoclonal antibodies.
3F10-HRP 6E4-HRP 6D11-HRP 3H12-HRP PK2-HRP
3F10 + + + +
6E4 - - + -
6D11 - - + +
3H12 - - - -
PK2 - - - -
identical epitope recognised by the 2 mAbs.different epitope recognised by the 2 mAbs.
The results obtained from competitive ELISA performed to explore the
epitopes recognised by these 5 mAbs were quite confusing. The experiment with
unconjugated PK2 did not seem to work. It was not possible to state with certainty
which monoclonals recognise the same structure on MmmSC CPS except maybe for
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6E4, 6D11, 3H12 and PK2 that seemed to recognise different epitope on MmmSC
CPS. As shown in Table 9, the results for the other mAbs were different according to
the order of incubation of the monoclonal antibodies, which could be explained by
overlapping epitopes or steric hindrance. The latter seems likely since IgM are huge
molecules associated together to form a pentamer. A different affinity of two mAbs
for the same CPS epitope might also explain these results. If one of these two
antibodies has a higher affinity for the epitope, when it is incubated in second
position (Le. conjugated to HRP), it could replace the antibody incubated in the first
step and consequently, it will look like these two antibodies recognise a different
epitope.
3.5. Passive immunisation.
With other microorganisms, it has been shown that CPS can give protection
against diseases caused by these organisms when administered as a vaccine [137]. Our
hypothesis was that if animals could elicit antibodies against mycoplasmal CPS, they
would be protected against disease caused by that organism. No successful
mycoplasma vaccines based upon purified CPS have yet been described. Mice were
used as an animal model for CBPP. They develop bacteraemia (without any signs of
disease) when inoculated intraperitoneally with MmmSC and a correlation was seen
between the virulence of MmmSC strains observed in mice and that observed in
cattle, based on the duration of mycoplasmaemia in mice, the most virulent MmmSC
strains producing a longest mycoplasmaemia [in]. To explore if anti-CPS antibodies
are protective against the disease, 10 mice (group I) were passively immunised with
purified mAb 3F10, which recognises MmmSC CPS, and 10 other mice (group II)
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were given PBS as negative control. Four mice (group III) did not receive any mAb
or PBS as a control for the bacteraemia. All mice were then challenged withMmmSC
strain N6 to see if protection occurred in the group given anti-CPS mAb 3F10. This
strain was chosen because it has been shown it produces a high degree of
mycoplasmaemia in mice [154]. Mycoplasmaemia was monitored by blood culture in
Gourlay's medium diluted at 10° and 10"1 (Table 10). The blood culture was diluted
at 10"1 because sometimes a slight colour change in the medium can be seen
following the addition of blood with no mycoplasma present. Mice were all free of
mycoplasmas before the beginning of the assay as all the pre-bleeds were negative.
Mice were bled 1 (Dl), 2 (D2), 3 (D3), 4 (D4) and 7 days (D7) after infection.
Table 10. Mycoplasmaemia in mice after passive immunisation.
Number ofmice showing mycoplasmaemia
B•0 B>1 B>2 B 3 B>4 B•7 GS
10° 10"1 10° 10-1 10° 10"1 10° 10"1 10° 10'1 10° 10'1
I 0 0 10 4 8 2 4 0 0 0 0 0 10
n 0 0 10 6 10 1 4 0 1 0 0 0 10
m 0 0 4 3 4 0 0 0 0 0 0 0 4
(I) Mice immunised with 3F10, anti-CPS antibody, and challenged withM/wwSC strain N6. (II) Mice
immunised with PBS only and challenged with MmmSC strain N6. (HI) Mice challenged with
MmmSC strain N6 only. GS: group size, number ofmice in each group. DO, Dl, D2, D3, D4 and D7:
days of bleeding, 10° and 10'1: mouse blood culture dilution.
No statistical difference could be seen in the duration and the extent of
mycoplasmaemia between mice having received PBS and mice having received mAb
3F10. Therefore, no protection against MmmSC using anti-CPS antibody was then
observed using this assay using this strain. These findings suggest that a bactericidal
antibody against MmmSC does not protect against the disease in vivo in a mouse. In
other studies [155], it has been observed that mice vaccinated with CPS conjugated to
ovalbumin, although exhibiting a higher immune antibody response to CPS than
mice vaccinated with CPS only, were not protected against infection with MmmSC.
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Mice immunised with sonicated mycoplasma, although showing a low anti-CPS
immune response, were protected against a challenge with live mycoplasma and did
not exhibit an inhibiting activity in their sera, suggesting the involvement of cell-
mediated immune response against MrnrnSC in mice.
Another explanation could be that the amount of antibody injected, was not
high enough to induce protection against mycoplasma in mice.
3.6. CPS immune response in cattle.
Current vaccines against CBPP are not very efficient and induce a short
lasting immunity. This lack of immunity could be due to a poor immune response
against CPS in vaccinated animals. Our hypothesis was that animals showing an
immune response against CPS would be protected against CBPP as it has been
shown in other microorganisms where vaccination with CPS protected against the
disease. First, we looked at the IgM immune response in a group of vaccinated
animals to see how many of them were immunologically positive against CPS. Then,
we determined the isotype (i.e. IgM, IgG and IgA) of the anti-CPS immune response
in three groups of cattle: vaccinated, intubated and unvaccinated in-contact animals.
IgM immune response was determined as, in a typical humoral immune response,
these are the major antigen-specific immunoglobulins to be produced. IgG is the
main antibody in a secondary immune response and IgA is present predominantly in
mucosal secretions [156], CPS is a thymus-independent antigen, meaning it does not
produce readily an immunological memory [i4oj. However, the degradation of
mycoplasmas in the lung could release pieces of membrane containing CPS and
proteins that could act like CPS conjugate which would therefore becomes a thymus-
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dependent antigen that could lead to affinity maturation of B cells and T cells,
isotype switching and then production of immunoglobulins other than IgM.
Bovine sera to be tested were from a trial performed in Kenya. The trial
consisted of 120 male local breeds of Kenyan cattle aged 3 or more selected at
random. All the animals were bled twice at the start of the trial. Two groups of 20
animals were vaccinated one month after the first pre-bleed (date of vaccination:
15-20/05/1998). Reconstituted freeze-dried Tj44 and TiSR vaccines were injected
subcutaneously. On the 21/09/1998, 40 animals were intubated with a virulent
MmmSC strain from Kenya. One week later (28/09/1998), the intubated animals
were put in contact with 40 unvaccinated cattle and the 40 vaccinated ones. Animals
were regularly bled 16 times from the beginning of the trial to the end (from
01/04/1998 to 29/01/1999).
3.6.1. CPS IgM immune response in vaccinated cattle.
CPS-specific IgM immune response in cattle vaccinated with Tj44 using
19 sera was assessed (Fig. 18). Half of the bulls exhibited a relatively high signal
(OD around 0.5) against CPS before vaccination (Fig. 18. D, E, I, J, K, L, M, O and
S). After vaccination, only 5 bulls showed a significant IgM immune response
against CPS (Fig. 18. A, B, C, F and G). After contact with intubated animals, bulls
67 (Fig. 18. F) and 114 (Fig. 18. H) exhibited an IgM immune response against CPS.
Bull 67 (Fig. 18. F) was the only animal showing an immune response following
both vaccination and after being in contact with intubated animals. However, the
IgM immune response was short since the level of IgM went back to normal 1 month
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after the peak of the vaccination and two weeks after the peak following the contact
with MmmSC
Fig. 18. IgM immune response againstMmmSC CPS in Ti44 vaccinated cattle.
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Fig. 18 (continued). IgM immune response against MmmSC CPS in Ti44 vaccinated
cattle.
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Fig. 18 (continued). IgM immune response against MmmSC CPS in Tj44 vaccinated
cattle.











































































0.000 t ' i i i- l l i i i I —-#i i i I i i i I I








00 00 oo CO 00 00
CD CD CD CD CD CD
K h» OO CO CD CD
O o O o O O
oo cM In CD CM CD





00 00 00 00 00 CD
CD CD O) o> CD CD
O T— cM cM T—
v— T— T— T— r— o
00 T— in CD CO 8CM T- CM O est oCM
















































s i» co si a o)
o o o o o o
CM O CM O - o
date
CO
00 00 00 CO 00 CO CD CD
CD CD CD CD CD CD CD g>
O O T— T— cM C\1 T~ T—
T— T- T— T— T— o o
CO T— in o> CO § oCM T— CM o CM CM
• date ofvaccination. date of contact withMn/nSC-intubated animals
106
Fig. 18 (continued). IgM immune response against MmmSC CPS in Tj44 vaccinated
cattle.
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Fig. 18 (concluded). IgM immune response againstMmmSC CPS in Ti44 vaccinated
cattle.
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3.6.2. CPS IgM, IgG and IgA immune response in MmmSC
intubated cattle.
The immune response against CPS in 5 intubated animals was measured. The
sera were from bulls chosen at random. Four out of 5 (Fig. 19. B, C, D and E)
exhibited an IgM immune response but none of them showed any IgG or IgA CPS-
specific sera.
Fig. 19. IgM, IgG and IgA immune response against MmmSC CPS in MmmSC-
intubated cattle.
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3.6.3. CPS IgM, IgG and IgA immune response in
unvaccinated in-eontact cattle with MmwiSC-intubated animals.
The sera were from bulls chosen randomly. The immunoglobulin isotype
response against CPS in 5 unvaccinated bulls placed in contact with intubated
animals was explored (Fig. 20). Bulls 3 (Fig. 20. A), 61 (Fig. 20. D) and 84
(Fig, 20. E) had a relatively high signal for the IgM immune response against CPS
before being put in contact with intubated animals. Two bulls (Fig. 20. A and E)
exhibited an IgM immune response against CPS after being in contact with intubated
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cattle. None of the animals, except bull 3 (Fig. 20. A), exhibited IgG specific for CPS
in their sera following challenge. No IgA specific for CPS were detected in any of
the in-contact bull sera following challenge.
Fig. 20. IgM, IgG and IgA immune response againstMmmSC CPS in unvaccinated
cattle in contact with MwmSC-intubated animals.
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Fig. 20 (concluded). IgM, IgG and IgA immune response against MmmSC CPS in
unvaccinated cattle in contact withMww/SC-intubated animals.
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3.6.4. CPS IgM, IgA and IgG immune response in
vaccinated cattle.
The immune response against CPS was investigated in 5 Tj44 vaccinated
animals placed in contact with intubated animals (Fig. 21). The sera were chosen
according to previous results (section 3.6.1.). Four of them showed an IgM-specific
immune response for CPS after vaccination (Fig. 21 A,B,C and D). Among the
vaccinated bulls, two exhibited an IgM immune response after being in contact with
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intubated bulls (Fig. 21. C and E), one of them did not respond to vaccination
(Fig. 21. E).
Fig. 21. IgM, IgG and IgA immune response against MmmSC CPS in Ti44
vaccinated cattle in contact with A//»wSC-intubated animals.
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Fig. 21 (concluded). IgM, IgG and IgA immune response against MmmSC CPS in
Ti44 vaccinated cattle in contact withMwwSC-intubated animals.
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3.6.5. Conclusions.
The class of immunoglobulin responses against CPS were investigated in
three different groups of cattle, MmmSC intubated bulls, unvaccinated bulls and Tj44
vaccinated bulls both placed in contact with MmmSC intubated animals, were
investigated. Firstly, in the group of vaccinated cattle, only 5 out of 19 (26%) had an
IgM immune response, in agreement with the fact that the current vaccine is not very
efficient in the protection against CBPP, if it is assumed the protection is conferred
by anti-CPS antibodies
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The immune response from the bulls in the three groups was only IgM type.
No IgG could be detected against CPS except for bull 3 in the group ofunvaccinated
cattle in contact with intubated animals. This could be explained because of the
nature of CPS, since the immune response against polysaccharides is predominantly
of IgM type. As the vaccinated bulls were in contact a second time with MmmSC, it
was expected some of them would exhibit CPS specific IgG in their sera. Even
though CPS is a polysaccharide, it could have induced the production of IgG since
hyperimmunised rabbit with MmmSC produced IgG specific for CPS. According to
the serological response against CPS, it appears that three different categories exist:
no response to CPS, response to CPS only after vaccination and response to CPS
both after vaccination and after contact with MmmSC intubated animals, though very
rare. It would have been interesting to compare the clinical and post-mortem data
from these bulls with the serological data: (i) to see if the animals showing immune
response to CPS were those exhibiting signs of disease, (ii) to compare the severity
of the lung lesions with the immune response to CPS, (iii) to examine if animals
vaccinated against MmmSC and showing CPS immune response to CPS were
protected against the disease.
3.7. Cross-reactions between CPS and normal bovine
lung.
Cross-reactions have been reported between bovine lung and MmmSC
CPS [102,105]. Previously, it was observed that in cattle vaccinated withMmmSC, only
a small proportion showed an immune response to CPS (see section 3.6.).
Unresponsiveness to CPS might be a consequence of this cross-reaction, as the
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lymphocytes recognising both the lung and CPS would be in a state of anergy or
deleted and could not be stimulated and consequently produce antibodies.
It was interesting to confirm the cross-reactions between bovine lung and
CPS using mAbs by western-blot (WB) as mAbs specific for CPS are more specific
than the polyclonal sera that were raised against the whole microorganism. Also
WBs are more accurate than agar-gel precipitin test (AGPT). Polyclonal sera and
AGPT were used in the earlier experiments showing cross-reaction between CPS and
bovine lung. It was also of the interest to examine if the different CPS epitopes are
also present on bovine lung. If one of them is different, it could be studied for its
protective activity and to be used as a vaccine. Of interest was whether antibodies
recognising both CPS and bovine lung would be present in MmmSC-infected cow
sera; if these sera recognise both CPS and lung, this could lead to immunopathology
in the lung. If only antibodies against CPS are present, these cattle might be
protected against the disease.
3.7.1. Western-blot with CPS and normal bovine lung using
anti-M/wiiSC cow and rabbit sera and anti-CPS mAbs.
Different sera were tested to see if they recognised both bovine lung
homogenate (consisting of disrupted normal bovine lung tissue in buffer, boiled in
loading buffer before being loaded in the gel) and bovine lung galactan and MmmSC
CPS. Sera were from MmmSC naturally-infected cows, M/wmSC-vaccinated cows,
MmmSC-hyper-immunised rabbits and CPS-vaccinated mice (CPS was conjugated to
ovalbumin). Five mAbs that recognise CPS were also used: 3F10, 6E4, 6D11, 3H12
and 2A3 (Fig. 22) (see section 3.4.). WB with CPS was used as a positive control
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(Fig. 22. A) and the signal was compared to that seen against bovine lung
homogenate (Fig. 22. B) and bovine lung galactan (Fig. 22. C). None of the HRP-
conjugated secondary antibodies reacted with CPS. Pre-immune cow serum gave a
positive signal with CPS (although this was low) whereas pre-immune rabbit and
mouse sera did not. The sera fromMwwSC-infected and -vaccinated cows, MmmSC-
immunised rabbits and CPS conjugate vaccinated mice showed a signal with CPS.
As expected, mAbs strongly recognised CPS. When the sera from cows, rabbits and
mice, and monoclonal antibodies were tested with bovine lung homogenate
(Fig. 22. B) and bovine lung galactan (Fig. 22. C), the similar results were observed
as those with CPS, the only difference came from HRP-conjugated anti-cow
immunoglobulin that cross-reacted with bovine lung homogenate and bovine lung
galactan. As a consequence, it was not possible to determine if the bovine sera gave a
signal or not (different secondary antibodies against bovine immunoglobulins were
tested unsuccessfully even after pre-absorption with bovine lung homogenate).
3.7.2. Western-blot with CPS and normal bovine lung using
mouse sera raised against bovine lung homogenate.
For further confirmation of the cross-reaction between bovine lung and CPS,
mice were immunised with bovine lung extract. The sera obtained were tested
against bovine lung (as a control) (Fig. 23. A) and against CPS (Fig. 23. B). HRP-
conjugated anti-mouse immunoglobulin antibody did not cross-react with bovine
lung homogenate. Pre-immune sera showed only a slight reaction with bovine lung
(pre-immune serum from mouse 10 was not available). As expected, the immune
sera from mice reacted strongly with bovine lung homogenate. The immune sera also
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showed a positive signal with CPS, in agreement with earlier data suggesting that the
two antigens shared epitopes. When tested with CPS, no reaction could be seen with
the conjugated secondary antibody and with the pre-immune sera.
Sera from mice 30 and 40 were tested in GIT against MmmSC strains Gemu
Goflfa and M375. None of them inhibited the growth of these mycoplasmas. It does
not prove that it did not contain inhibiting antibodies since the sera from mice
immunised with CPS conjugated to ovalbumin exhibited antibodies to CPS but did
not have growth inhibiting activity [iss].
Fig. 22. Immunoblots showing cross-reactions between MmmSC CPS as antigen and
normal bovine lung homogenate and galactan as antigen using anti-MmwSC sera and
CPS monoclonal antibodies.
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Fig. 22 (concluded). Immunoblots showing cross-reactions betweenMmmSC CPS as
antigen and normal bovine lung homogenate and galactan as antigen using anti-
MmmSC sera and CPS monoclonal antibodies.
B) Bovine lung homogenate immunoblot
C) Bovine lung galactan immunoblot
bovine sera rabbit sera mouse sera
^0 weeks post-vaccination bleed, 22 weeks post-vaccination bleed.
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3.7.3. Conclusions.
The results obtained with these WBs suggested that epitopes from CPS were
also present on bovine lung. However it was not possible to determine if antibodies
recognising both CPS and bovine lung were present in cow sera as the HRP-
conjugated anti-cow immunoglobulin antibody reacted with bovine lung. It should be
noted that the pre-immune cow serum showed a signal against CPS though lower,
indicating that in a normal state, antibodies that recognise carbohydrate epitopes that
can be found on CPS are present in a cow with no past of contact with MmmSC.
Although only one serum was tested in this assay, another experiment, using
15 normal cow sera (from cows bred in the United Kingdom) tested by ELISA
against CPS, showed that 11 of them exhibited a signal with an optical density higher
than 0.5 against CPS although these cows never encountered MmmSC (data not
shown). It is not known why antibodies that can bind to CPS are present in these
sera; it can be speculated that these cows react to factors present in their environment
(microorganisms, food...). This possible cross-reaction was explored. The results are
exposed in the following section.
3.8. Cross-reactions between CPS and carbohydrates
from cereals.
The use of CPS as a vaccine would require to grow MmmSC in large
quantities then to purify the supernatant, a procedure that needs time and a lot of
handling and adequate laboratory facilities to culture the mycoplasmas. It has already
been shown using anti-MwwSC polyclonal bovine serum [cited in 102] that MmmSC CPS
shared epitopes with a variety of compounds such as polysaccharides from other
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bacteria, barley and oat glucans. Thus, these polysaccharides might replace CPS to
make a vaccine. Cereals are a common source of carbohydrates, these carbohydrates
may share epitopes with CPS but the use ofmAbs will permit the identification more
specifically of the common epitopes between CPS and cereal carbohydrates. Crude
carbohydrates were purified from different cereal preparation: corn flour, oatmeal,
rice, wheat flour and wheat semolina and investigated in western blot (WB)
(Fig. 24. B, C, D and E respectively). CPS purified from MmmSC strain V5 grown in
casein medium was used as a positive control (Fig. 24. A). Cow and rabbit immune
sera against MmmSC and mouse anti-CPS antibodies (mAbs and polyclonal sera)
were used in these assays.
None of the secondary antibodies cross-reacted with the carbohydrate
extracts. Cow pre-immune and vaccinated-immune sera gave a signal with all the
different carbohydrate solutions and CPS. The serum from the rabbit immunised with
MmmSC strain N6 recognised the different preparations of carbohydrates and CPS.
Pre-immune serum from the same rabbit did not showed any signal except with the
corn flour extract, a slight signal was also shown with CPS. Four out of the 5 mAbs
(3H12, 2A3, 3F10 and 6E4) presented a signal with all carbohydrate extracts. MAb
6D11 recognised wheat flour extract only (Fig. 24. D) as the same results were
obtained on repeating assays. As expected, all mAbs reacted with CPS (Fig. 24. A).
These results suggested that epitopes on CPS might be relatively common
because they can be found on other carbohydrates, found readily in nature. MAb
6D11 recognised wheat flour extract but not wheat semolina extract. This could be
explained by a different strain of wheat, or by a difference in wheat treatment to
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make these products, since one of these treatments could "present" a new epitope on
the molecule or destroy it.
Fig. 24. Immunoblots showing cross-reaction betweenMmmSC CPS as antigen and
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3.9. Role of CPS in adhesion.
In other microorganisms, differences in adhesion have been related to the
presence or absence of CPS [129,130]. The role ofMmmSC CPS in adhesion has never
been explored so far. It was then decided to study the role of CPS in this process by
an indirect way in an adherence inhibition assay in tissue-culture plates.
MmmSC strains N6 and M375 and M. bovis strain PG45 were pre-incubated
with a different mAb. Anti-MmmSC CPS mAb 1C9 was used with the strain N6,
anti-M bovis mAb 4D7 was used with the strains M375 and PG45. The hypothesis
was that if CPS plays a part in adhesion of MmmSC, the addition of anti-CPS
antibody should inhibit the adhesion to embryonic bovine lung (EBL) cells. M. bovis
strain PG45 with mAb 4D7 was used as a positive control, i.e. the addition of mAb
4D7 has been shown to inhibit the adhesion of strain PG45 to EBL cells. MmmSC
strain M375 could not be pre-incubated with mAb 1C9 due to the small amount of
this antibody; it was therefore decided to incubate this strain with mAb 4D7. In this
case, no inhibition in the adhesion ofM375 was expected.
The results obtained from mycoplasmas pre-incubated with mAbs were
compared with those obtained from mycoplasmas without mAbs to determine the
relative adherence rate. The results are shown in Fig. 25.
The results obtained from the adherence assay were not conclusive. The
results obtained from the MmmSC strain N6 could not show whether MmmSC CPS
was involved in adhesion of mycoplasmas because, even though no inhibition of the
adhesion could be seen with 6.1 pg and 56.1 pg of mAb 1C9, the adhesion ofN6 to
EBL cells was nearly doubled in presence of 25.5 pg of antibody. The positive
control, M. bovis strain PG45, showed an inhibition of the adhesion with 43.5 pg of
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mAb 4D7 but not with 60.9 fig and 87 pg of mAb 4D7 where the inhibition of the
adhesion was expected to be higher than with 43.5 pg of antibody. No inhibition of
the adhesion of MmmSC strain M375 was expected since this strain was pre-
incubated with a non-specific mAb. It appeared as if the addition of mAb 4D7
increased the adhesion of M375 to EBL cells since the relative adherence rate was
twice more important in presence of antibody when compared with the adhesion in
absence of antibody, i.e. the relative adherence rate was 100 for M375 without mAb
and was more than 250 for M375 with 87 pg ofmAb (the experiment was performed
in duplicate and the results were consistent between the duplicates). This seemed
unlikely since mAb 4D7 was not supposed to bind to the MmmSC strain and the use
of this mAb induced the inhibition of adhesion ofM. bovis in previous experiments
[Konrad Sachse, personal communication].
Fig. 25. Adhesion of different mycoplasma strains, in presence of mAbs, to EBL
cells.
amount of antibody (microg)
♦: MmmSC strain N6 pre-incubated with anti-Mn/nSC CPS mAb 1C9, •: MmmSC strain M375 pre-
incubated with anti-Mbovis mAb 4D7, ▲: Mbovis strain PG45 pre-incubated with anti-AJbovis mAb
4D7.
It was not possible to show whether CPS was involved in adhesion in the
adherence inhibition assay in tissue-culture plates. A western-blot adherence assay
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was then performed to study the direct adhesion of EBL cells to mycoplasma
components.
An example of a SDS-PAGE of mycoplasmas is given in Fig. 26. The gel
stained with Coomassie Blue showed numerous proteins. CPS, although not stained
on this gel, is localised on the top of the gel. The adhesion of EBL cells to
mycoplasma was visualised by autoradiography of the nitrocellulose membrane
(Fig. 26.). The results from the autoradiography were not very good since the signal
was rather weak for most of theMmmSC strains used in the experiment.
No signal could be seen on the top of the autoradiography for any of the
MmmSC strains, suggesting that CPS is not involved in the adhesion ofMmmSC to
EBL cells. However, it cannot be excluded that the lack of signal could be due to the
poor exposure of the autoradiography.
Many proteins of MmmSC strains M375 and N6 interacted with EBL cells.
This would mean that these proteins are all adhesins which seems unlikely. The
different peptides might be degradation fragments from a single high-molecular-
weight protein that binds to EBL cells or represent a family of variable proteins
expressed on the surface of the mycoplasma. These results might also be due to a
non-specific binding to the EBL cells.
127
Fig. 26. Western-blot adherence assay of MmmSC strains with radiolabeled EBL
cells
SDS-PAGE ofMmmSC strains autoradiography of the nitrocellulose
membrane after WB adherence assay
It was not possible to determine the role of MmmSC CPS in adhesion from
the results of the adherence inhibition assay and the western-blot adherence assay.
The identification ofMmmSC adhesins was not possible either since the results of the
autoradiography for MmmSC strains M375 and N6 showed too many bands,
suggesting that these bands were due to a non-specific binding to the EBL cells or
that they were degradation products from a single protein or variable proteins.
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4. Discussion.
Vaccination seems the only way to eradicate contagious bovine
pleuropneumonia (CBPP) in Africa since the political and economical situations in
the affected countries cannot allow the funding of a policy of slaughter and
compensation as a policy of eradication. The current vaccines are not efficient
enough against CBPP [28.90,9ij. Therefore a new, better vaccine is needed. A capsular
polysaccharide (CPS), produced by Mycoplasma mycoides subsp. mycoides
(MmmSC), appears to offer good potential as a vaccine since it is a virulence
factor [no]. In addition, in other microorganisms, CPS has been shown to protect
bacteria against phagocytosis and antibodies against CPS and pneumococcal and
meningococcal CPS-conjugate vaccines have been shown to protect against the
disease [145,146].
4.1. CPS immunogenic structure.
An efficient vaccine is one able to protect against the different strains of the
targeted microorganism. The analysis of CPS by growth inhibition test (GIT) with
polyclonal antisera raised against different strains of MmmSC has shown that the
epitopes responsible for the growth inhibiting (GI) activity were present in all
MmmSC strains. In general, the sera with the highest anti-CPS titres had the greatest
GI activity. This suggested that antibodies against CPS were protective against
MmmSC. However, some exceptions occurred. The serum raised against MmmSC
strain 425 had a low CPS-specific antibody titre when compared to most of the sera
but exhibited a good GI activity against different MmmSC strains. Conversely, the
serum raised against MmmSC strain Filfili had a very high anti-CPS antibody titre
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but its GI activity was very low. This could be explained by the property of the anti-
CPS antibodies: not all antibodies against CPS might have GI activity. In the case of
the anti-425 serum, the total amount of CPS-specific antibodies may be low but most
of them might be growth inhibiting, whereas in the anti-Filfili serum, the total
amount of anti-CPS antibodies may be high but with only a small portion exhibiting
a GI activity. In addition, other components of the mycoplasmas might elicit GI
antibodies, i.e. CPS-non-specific antibodies might be bactericidal.
Our results in the GIT suggested that MmmSC CPS was probably conserved
between strains. This was further confirmed by an en2yme-linked immunosorbent
assay (ELISA) performed with different anti-CPS monoclonal antibodies (mAbs)
where the CPS purified from different MmmSC strains were all recognised by the
mAbs 6D11, 3F10, 3H12, 6E4, PK2, 2A3 and 1C9, except for the type strain PG1.
For this strain, mAbs PK2 and 2A3 gave a low signal by ELISA, suggesting the
epitopes recognised by these two mAbs were not present on PG1 CPS. The mAbs
6D11, 3F10, 3H12, 6E4 and PK2 tested in GIT showed all GI activity against
MmmSC strain Gemu Goffa.
The ELISA with different MmmSC CPS incubated with different mAbs was
also performed using CPS purified from Mycoplasma capricolum subsp.
capripneamoniae (Mccp) strains. MmmSC and Mccp are both classified in the
"Mycoplasma mycoides cluster". Mccp causes contagious caprine pleuropneumonia
in goats. No cross-reaction could be seen between MmmSC CPS and Mccp CPS
although their sugar composition was reported as being very similar (fucose,
mannose, galactose, glucose, galactosamine and glucosamine in an approximate ratio
of 1:2:4:1:4:8 and fucose, mannose, galactose, glucose, galactosamine and
130
glucosamine in approximately equal quantities, respectively) [97,157]. However, the
MmmSC and Mccp strains used for the determination of CPS composition in these
two publications were both cultured in Gourlay's broth. A high molecular weight
carbohydrate, extracted from this culture medium, was subsequently shown to
contaminate solutions of purified CPS [iso]. Therefore, it is possible that this
similarity between the CPS from these two species is due to contamination with
carbohydrate culture medium. Another explanation could be that the two
polysaccharides contain the same sugars but are structurally dissimilar and present
different epitopes.
Two other mycoplasma species, Mycoplasma mycoides subsp. mycoides large
colony (MmmLC) and Mycoplasma mycoides subsp. capri (Mmc), are also classified
in the Mycoplasma mycoides subgroup along with MmmSC. These two mycoplasma
species are difficult to identify from each other, and many Mmc isolates have been
reclassified as MmmLC [cited in i58]. It has been suggested that MmmLC and Mmc
should be re-classified as a single species according to their 16S rRNA sequence
analysis and their tRNA profile [131,152]. In addition, MmmLC and MmmSC have been
shown to share immunological similarities, since anti-Afrn/wLC polyclonal sera
inhibited the growth ofMmmSC strains [cited in 153]. Five mAbs recognising CPS of
MmmSC (3F10, 6E4, 6D11, 3H12 and PK2) were used in an ELISA against 7
MmmLC strains (UM30847, G8, G10, Y goat, 2/93, 247/4 and 5307) and 5 Mmc
strains (133/87, WK354, L, PG3 and BQT). Six MmmLC strains (UM30847, G8,
G10, Y goat, 2/93 and 247/4) and two Mmc strains (133/87 and WK354) were
recognised by both 3F10 and 6E4. Three MmmLC strains (UM30847, G10 and
Y goat) and the Mmc strainWK354 were recognised by 6D11. MAbs 3H12 and PK2
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did not exhibit a signal against any of the MmmLC and Mmc strains. This suggested
that the CPS of the "MmmLC/Mmc" species and CPS ofMmmSC exhibit antigenical
differences.
The same mAbs were used against these MmmLC and Mmc strains in GIT.
MAbs 3F10 and 6E4 exhibited growth inhibiting activity against all MmmLC and
Mmc strains recognised in the previous ELISA except for MmmLC strain G8.
MmmLC strain 2/93 was inhibited by 3F10 but not by 6E4 (both mAbs recognised
this strain by ELISA); this might be due to a greater CPS production by G8 and 2/93
when compared to the production of CPS by the otherMmmLC strains. None of the
other mAbs (6D11, 3H12 and PK2) were inhibitory against any MmmLC and Mmc
strains tested. The results obtained with PK2 in GIT were in agreement with those
obtained in an experiment which showed that PK2 inhibited 9 MmmSC strains but
did not inhibited any of the 3 MmmLC strains used in GIT [i53].
The results obtained with the ELISA and the GIT suggest that the mAbs can
be divided into three categories: (i) mAbs binding to MmmLC/Mmc CPS and
exhibiting GI activity against some MmmLC and Mmc strains (3F10 and 6E4), (ii)
mAbs binding to MmmLC/Mmc strains with no GI activity against MmmLC and
Mmc strains tested (6D11) and (iii) mAbs that do not bind to MmmLC/Mmc CPS and
showing no GI activity against MmmLC and Mmc strains tested (3H12 and PK2).
Data suggest that CPS contains at least three different epitopes.
MmmLC strains and Mmc strains were not all recognised by the mAbs, i.e.
some strains were recognised by the mAbs and some others were not, suggesting two
"serotypes", based on CPS. To our knowledge, this would be the first time that it has
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been described in mycoplasmas. It would then be suggested to re-classify MmmLC
andMmc as a single species with two serotypes.
As described in the previous paragraphs, results suggested that at least three
different epitopes were recognised by the mAbs, meaning that at least three different
epitopes exist on MmmSC CPS. To explore further the number of epitopes
recognised by the different mAbs, a competition ELISA was performed.
Unfortunately, it was not possible to state with certainty which mAbs recognise the
same structure on MmmSC CPS except maybe for 6E4, 6D11, 3H12 and PK2 that
seemed to recognise different epitope on MmmSC CPS. The results for the other
mAbs were different according to the order of incubation of the mAbs, which could
be explained by overlapping epitopes, steric hindrance or affinity difference for the
same CPS epitope.
We have shown that MmmSC CPS was conserved between MmmSC strains
and that the molecule presented at least three different epitopes. As a consequence,
the CPS from only oneMmmSC strain could be used in vaccination against CBPP.
4.2. CPS as a vaccine.
In the precedent section, antibodies against CPS were shown to be
bactericidal in vitro suggesting these antibodies were protective against MmmSC. It
is not known whether anti-CPS antibodies are protective in vivo. Ideally, the best
model to explore the protective efficacy of CPS-specific antibodies in vivo would be
cattle. Unfortunately, it is not possible due to the size of the animal and the cost this
would involve to maintain cattle in containment. Therefore, it was decided to use
mice as a preliminary assessment ofanti-CPS antibody efficacy against MmmSC.
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To explore the protective effect of anti-CPS antibodies against CBPP, mice
were passively immunised with purified bactericidal mAb 3F10, then challenged
withMmmSC strain N6. As this mAb is bactericidal, it seemed likely it might protect
against the disease. When compared with the group of mice immunised with PBS
then challenged with N6 strain, mice that had received the injection with mAb 3F10
did not show a significant difference in the incidence and duration of
mycoplasmaemia. These results suggested that in vivo, the bactericidal mAb was not
protective against MmmSC strain N6 in mice. These results were in agreement with a
study showing that mice immunised with a MmmSC CPS conjugate vaccine,
although showing an immune response to CPS, were not protected against challenge
with MmmSC. Mice immunised with whole inactivated MmmSC, although having a
low CPS-specific antibody titre in their sera, were protected against infection with
MmmSC but these sera did not exhibit a growth inhibiting activity [issj. These results
suggested that in mice, the protection against MmmSC was cell mediated rather than
humoral.
Current vaccines against CBPP are not very efficient. They induce a short-
lasting immunity and do not protect all vaccinated cattle [28,90,91]. This lack of
protection might be due to a poor immune response to CPS, assuming that the
protection against MmmSC in cattle is due to anti-CPS antibodies. Therefore, it was
decided to analyse the CPS immune response in various cattle. The immune response
against CPS in three groups of cattle was examined. The groups were (i) Ti44-
vaccinated cattle subsequently placed in contact with MmmSC-intubated cattle, (ii)
Mm/wSC-intubated cattle and (iii) unvaccinated cattle placed in contact with
MmmSC-intubated cattle (i.e. group II). Only 26% of vaccinated cattle showed an
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immune response to CPS after vaccination as measured by ELISA, in agreement with
the lack of efficacy of the vaccine (assuming the protection against CBPP is from
antibodies against CPS).
A typical primary immune response to an antigen consists mainly of IgM
class antibodies. When the host is confronted a second time with the same antigen, a
typical secondary immune response is composed mainly of IgG class antibodies,
which exhibit a higher affinity for the antigen. The immune system also responds
faster. Examining the immune response in more detail in the experiment described in
the previous paragraph, only IgM class antibodies were detected in the three groups
of cattle. No IgG or IgA could be detected against CPS except for a single
unvaccinated "in-contact" bull, which showed a low level IgG immune response. IgG
responses were especially expected in sera from vaccinated cattle following "in-
contact" challenge since they were exposed twice to MmmSC. CPS on its own is a
poor immunogen. As a T-independent antigen, it does not induce memory B cells
and antibody class switching. But in a vaccine or following infection, CPS is
presented with MmmSC proteins, which could behave as protein carriers. CPS could
therefore become a T-dependent antigen, enabling antibody class switching from
IgM to IgG to occur. This seems to be possible since rabbits immunised with
MmmSC exhibit a good IgG antibody response against CPS. The lack of IgA
immune response was less surprising as IgA is the predominant immunoglobulin in
seromucous secretions such as tracheo-bronchial secretions and we only looked at
the IgA immune response in sera. Since CBPP is a respiratory disease, it would have
been interesting to investigate the immune response against CPS in lung lavages of
the same group of cattle.. It would also have been interesting to compare the
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serological data with the clinical and post-mortem data to see if the CPS immune
response was correlated with the severity of lung lesions and with protection against
CBPP.
The observed lack of immune response against CPS in vaccinated cattle
might be the consequence of the reported cross-reaction between bovine lung and
CPS, with autoreactive B cells being anergised or deleted to prevent damage to the
host (i.e. the similarity between the host lung and MmmSC CPS could cause
immunotolerance or immunopathology). This cross-reaction was further investigated
by western-blots (WBs) using sera raised against bovine lung homogenate and CPS
from different animals. The sera from MmmSC immunised rabbits, CPS-conjugate
vaccinated mice and CPS mAbs gave a signal against both CPS and bovine lung. The
sera from MmmSC naturally-infected cows and from MmmSC vaccinated cows
showed a positive signal against CPS but it was not possible from these experiments
to determine if bovine antisera cross-reacted with bovine lung homogenate and
bovine lung galactan due to a non-specific signal from the secondary antibody
(different secondary antibodies against bovine immunoglobulins still exhibited this
non-specific signal even after pre-absorption with bovine lung homogenate). Cow
pre-immune serum was also positive for CPS but the signal was a lot weaker than the
signal observed with sera from infected and vaccinated cows that showed a response,
whereas rabbit and mouse pre-immune sera did not show a signal against CPS. The
results obtained with the cow pre-immune serum could be considered as a
background reaction, since sera from cattle with no history of CBPP were shown in
this thesis to react positively with CPS in an ELISA. This background reaction could
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be due to exposure to other polysaccharide antigens found in foodstuffs or from other
microorganisms, i.e. these polysaccharides might give cross-reactions with CPS.
These results confirmed the cross-reaction between bovine lung and CPS.
Furthermore, the different epitopes recognised by the different mAbs, which were
shown to be bactericidal against MmmSC strain Gemu Goffa, were also all present
on bovine lung, i.e. all CPS mAbs bound to the bovine lung. The cow immune
response against bovine lung homogenate and bovine lung galactan would have been
of a particular interest. Although rabbit and mouse sera showed cross-reactions
between the bovine lung and MmmSC CPS, the sera from cows might have shown a
different result, i.e. cow sera could have shown a signal against CPS and not the
bovine lung since CPS might have epitopes that cannot be found on bovine lung. If
antibodies against bovine lung had been detected in cow sera, this would have given
evidence of immunopathology.
The cross-reaction between bovine lung and CPS was also confirmed by the
reciprocal experiment i.e. the use of anti-bovine lung mouse sera which gave a
positive signal against CPS as well as against bovine lung homogenate as expected.
In the WB with MmmSC CPS as antigen, pre-immune cow sera gave a
positive, although weak, signal against CPS. This reaction is not uncommon since in
15 sera from cows free of CBPP (bred in the United Kingdom), 11 of them showed a
similar background reaction with CPS in an ELISA (optical density (OD) above 0.5)
[J.B. Marrh, unpublished results]. This background signal reaction was also visible in the
ELISA with vaccinated and unvaccinated cattle in which pre-immune bleeds showed
an OD close to 0.5, but following vaccination or being placed in contact with
M/nmSC-intubated cattle, an increase in the immune response to CPS occurs in some
137
cattle. This background might be caused by antibodies raised against polysaccharides
from foodstuffs or against CPS from other microorganisms. It has been reported that
MmmSC CPS shared epitopes with polysaccharides from different sources (bacteria,
barley, oat glucans...) [citedin 59]. Therefore dietary exposures might have led to this
background signal in many cattle.
To minimise the cost of CPS vaccine production, polysaccharides from other
sources, such as cereals, could be used. Carbohydrates purified from com flour,
oatmeal, wheat flour and wheat semolina reacted with pre-immune cow sera,
MmmSC-vaccinated cow sera, MmmSC-immunised rabbit serum and mAbs 3H12,
2A3, 3F10 and 6E4. An additional mAb, 6D11 also reacted with wheat flour
carbohydrate. These results suggested that different epitopes of CPS might be very
common in the environment. As a consequence, they might not be very
immunogenic, hence difficult to mount an effective immune response.
Since the mAbs, which recognised epitopes on CPS and cereal carbohydrates,
have bactericidal activities, this means that these polysaccharides could elicit
protective antibodies if used in a vaccine. But due to the nature of these molecules,
they would need to be given in an effective manner such as conjugated to proteins.
4.3. Conclusions.
MmmSC CPS possesses at least three different epitopes. These epitopes are
found readily in nature since MmmSC CPS shares epitopes with carbohydrates from
cereals such as wheat flour, rice, oatmeal and wheat semolina. In addition, these
epitopes are also present in bovine lung.
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We have shown that cattle vaccinated with Ti44 exhibited poor immune
responses to CPS. According to the hypothesis that CPS is the protective antigen
against CBPP since anti-CPS antibodies are bactericidal in vitro, the lack of CPS-
specific antibodies could explain the poor efficacy of current vaccines. Passive
immunisation with anti-CPS antibodies proved unsuccessful in mice. However, this
does not mean that the same results would occur in cattle. The success with other
CPS vaccines for other microorganisms should lead to further study on the potential
ofCPS as a vaccine against CBPP.
An adhesion assay could be carried out to explore the role of CPS in the
adhesion ofMmmSC to the bovine respiratory tract (i) by comparing the adhesion
between MmmSC strains producing a lot of CPS and strains producing less CPS to
see if there is any difference that could be due to the production of CPS and (ii) by
comparing the adhesion between a MmmSC strain and the same one but pre-
incubated with CPS-specific antibodies. Efforts should also be made to determine the
exact structure of CPS by chemical analysis, mass spectrometry and nuclear
magnetic resonance of a pure solution of CPS without any polysaccharide
contaminant from the culture medium. Oligosaccharides of known sugar composition
and structure could be used for epitope mapping in an ELISA with anti-CPS
monoclonal antibodies to identify the bactericidal epitopes. The anti-CPS antibodies
could also be used to identify molecular mimics or to screen peptides library or to
produce anti-idiotype antibodies to be used as an alternative to CPS in vaccination.
In mice, the protection against MmmSC seems to be through cellular immune
response. Consequently, it would be interesting to examine the cellular immune
response to CPS in these animals by looking at the type of cytokines produced after
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vaccination and infection with whole mycoplasmas and CPS-conjugates. This could
be done in different species of mice, i.e. mice deficient in B cells, deficient in the
production of interferon y for instance. The cellular immune response to CPS could
also be examined in different groups of cattle (Tj44 or TiSR vaccinated cattle,
M/wmSC-infected cattle by contact withMwwSC-intubated cattle, M/nmSC-intubated
cattle themselves).
Cattle could be vaccinated with MmmSC CPS-conjugates to determine the
protection efficacy of this vaccine in cattle against challenge with MmmSC and to
look at a possible pathology in the lungs brought on by vaccination. The immune
response to CPS in these vaccinated cattle should also be analysed i.e. whether it is a
humoral or cell-mediated immune response. The effect of adjuvant and the route of
administration of the CPS conjugate vaccine on protection should also be
investigated. Intranasal vaccination might be more effective in eliciting protection
since this is the route ofnatural infection.
But more importantly, since cross-reaction between CPS and bovine lung is
suggested, it would be helpful to identify protective epitopes present on CPS but not
on bovine lung by screening bovine lung galactan with many anti-CPS antibodies of
which the recognised epitopes are known.
4.4. Role of CPS in MmmSC adhesion.
In Klebsiella pneumoniae, it was shown that encapsulated strains colonised
the intestinal tract and adhered to mucus-producing epithelial cells more efficiently
than the non-capsulated strains [129,130]. In Bacteroides fragilis, it was suggested that
carbohydrates present on the surface of the microorganism were involved in the
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adhesion to human intestinal cells [159]. The role of MmmSC CPS in adhesion has
never been studied. Adherence inhibition assay in tissue-culture plates (with anti-
MmmSC CPS mAb used as inhibitor) and western-blot adherence assay, using
embryonic bovine lung (EBL) cells, were performed to study the involvement of
CPS in adhesion ofMmmSC. Since MmmSC are bovine mycoplasmas infecting the
lungs, EBL cells were preferred to perform the experiments.
Unfortunately, the results of both experiments were inconclusive concerning
the part of CPS in adhesion.
Adherence inhibition assay did not seem to work since "illogical" results
were obtained. The addition of anti-MmmSC CPS mAb 1C9 to MmmSC strain N6
did not produce any inhibition of the adhesion at 6:1 pg and 56.1 pg, but when added
at 25.5 pg, an increase in the adhesion could be observed. Anti-M bovis mAb 4D7
was inhibiting only when added toM bovis strain PG45 at 43.5 pg. When mAb 4D7
was added at 60.9 pg and 87 pg, an increase in the adhesion of PG45 to EBL cells
could be seen. Finally, the addition of mAb 4D7 to MmmSC strain M375 increased
the adhesion of the mycoplasma strain to EBL cells while it should have had no
effect on the adhesion of M375. Clearly, these experiments need repeating. A
monoclonal antibody other than 1C9 should be used since it is not known if this mAb
is bactericidal and this property might affect the result, i.e. bactericidal antibody
might inhibit the adhesion of mycoplasmas to EBL cells. It would also be better to
use higher concentrations of antibody to be sure that a maximum ofmycoplasmas are
coated of antibodies.
Western-blot adherence assay did not give better answers about CPS and
adhesion. Since CPS is a high molecular weight polysaccharide, it is found on the top
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of the gel in a SDS-PAGE. As a consequence, any binding of EBL cells to CPS
would appear at the top of the autoradiography film. No signal was observed on the
top of the autoradiography, suggesting MmmSC CPS was not involved in the
adhesion to EBL cells. However, due to the poor exposure of the autoradiography, it
cannot be excluded that the signal was not strong enough. Many proteins (around 15)
for the MmmSC strains M375 and N6 seemed to bind to EBL cells. It is unlikely that
MmmSC possesses so many adhesins. Many of them might interact with EBL cells
by a non-specific binding. Some of these proteins could have been denatured by the
SDS-PAGE and this would then allow the adhesion to the EBL cells that would not
occur in vivo. They also might come from the degradation of a single high molecular
weight protein or represent a family ofvariable proteins.
Little is known about MmmSC adhesion. Other mycoplasma species have
been shown to adhere to various receptors such as sialoglycoconjugates receptors,
sulfatide receptors, to proteins and glycoproteins [i60] and major adhesins have been
identified like PI [i6i] and P30 [162] for Mycoplasma pneumoniae, P140 for
Mycoplasma genitalium [163] and pMGA for Mycoplasma gallisepticum [i64].
Adhesion of mycoplasmas to host cells could play a role in pathogenicity. Then, the
identification of host cell receptors for MmmSC and molecules involved in the
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SDS gel:
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Semi-dry blot buffer for WB:
Tris 5.82 g
glycine 2.93 g
10% SDS solution 3.75 ml
distilled water volume up to 1 1
STE buffer:
NaCl 0,438 g
TE buffer 40 ml
(10 mM Tris 1 mMEDTA buffer, pH 8)
adjust to pH 8
adjust to 50 ml with TE buffer
Silver equilibration solution:
Silver concentrate 75 pi





volume up to 30 ml
Tris-glycine running buffer for SDS-PAGE:
10 X Tris-glycine buffer 100 ml
distilled water 890 ml
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